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ABSTRACT 
 
 
Overexpression of HOXB4 in hematopoietic stem cells (HSCs) leads to increased 
self-renewal without causing hematopoietic malignancies in transplanted mice. The 
molecular basis of HOXB4-mediated benign HSC expansion in vivo is not well 
understood. To gain further insight into the molecular events underlying HOXB4-
mediated HSC expansion, we analyzed gene expression changes at multiple time points 
in Lin
-
Sca1
+
c-kit
+
 (LSK) cells from mice transplanted with bone marrow (BM) cells 
transduced with a MSCV-HOXB4-ires-YFP vector. A distinct HOXB4 transcriptional 
program was reproducibly induced and stabilized by 12 weeks after transplant. Dynamic 
expression changes were observed in genes critical for HSC self-renewal as well as genes 
involved in myeloid and B cell differentiation. Prdm16, a transcription factor associated 
with human acute myeloid leukemia (AML), was markedly repressed by HOXB4 but 
upregulated by HOXA9 and HOXA10, suggesting that Prdm16 downregulation was 
involved in preventing leukemia in HOXB4 transplanted mice. Functional evidence to 
support this mechanism was obtained by enforcing co-expression of sPrdm16 and 
HOXB4, which led to myeloid expansion, and leukemia. Before the onset of leukemia 
decreased HSC frequency was observed in HOXB4and sPrdm16 co-expressing cells, 
suggesting sustained expression of Prdm16 abolished HOXB4-mediated HSC expansion. 
Altogether, these studies define the transcriptional pathways involved in HOXB4 HSC 
expansion in vivo and identify repression of Prdm16 transcription as a mechanism by 
which HOXB4 mediates a benign HSC expansion. 
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CHAPTER 1.    INTRODUCTION 
 
 
Hematopoiesis 
 
All the blood cells are continuously generated by hematopoietic stem cells 
(HSCs) throughout life. Maintenance of hematopoietic system homeostasis and 
replenishment of mature blood cells rely on the self-renewal capacity and multipotency of 
HSCs. Hematopoiesis includes adult and embryonic hematopoiesis, which arises from 
different hematopoietic organs and undergoes distinct biology process. So far the murine 
hematopoietic system is the best understood of all species. 
 
 
Adult hematopoietic hierarchy 
 
Hematopoiesis is the process of production, multiplication and specification of 
blood cells in the bone marrow. With a combination of cell surface marker expression 
and functional assays, the hierarchical structure of the hematopoietic system was 
achieved (Figure 1-1). HSCs are the first well-characterized tissue-specific stem cells 
with self-renewal and multipotency and reside at the top of the hierarchy. HSCs give rise 
to the multipotent progenitor (MPP)
1,2
 which further differentiated into two oligopotent 
progenitors: the common lymphoid progenitor (CLP)
3
 and the common myeloid 
progenitor (CMP).
4
 CMPs then give rise to megakaryocyte-erythrocyte progenitors 
(MEPs) and granulocyte-macrophage progenitors (GMPs). These downstream 
oligopotent progenitors then give rise to all of lineage-committed effector cells and 
downstream mature blood cells. 
 
However, recent studies suggested that alternative models for lineage 
commitment during hematopoiesis should be considered. In 2008 Bhandoola’s gourp 
demonstrated that the earliest thymic progenitors (ETPs) are not derived from lymphoid-
restricted progenitors but from multipoient bone marrow progenitors, which lose B 
potential either prethymically or intrathymically.
5
 Almost all ETPs derived from 
multipotent progenitors possess both T and myeloid potential within the thymus.
5
 Later 
on Stuart H. Orkin’s group proposed an alternative mouse hematopoietic hierarchy from 
single-cell expression data which indicated that the MegE lineage priming occurred 
within highly enriched HSCs.
6
 This is different from the model proposed by Jorden 
Adolfsson et al and Cornelis J.H. Pronk et al which placed MegE lineage downstream of 
MPP and CMP.
7,8
 
 
 
Embryonic hematopoiesis 
 
The first wave of hematopoiesis starts in the extraembryonic yolk sac at E7.5 and 
later in allantois and placenta. However functional experiment showed that hematopoietic 
cells generated in yolk sac prior to E9.5 lack colony forming unit-spleen (CFU-S)
9
 and 
lack definitive HSCs prior to E11.5.
10,11
 The aorta-gonad-mesonephros (AGM) region of  
 2 
 
 
Figure 1-1. The hierarchy of hematopoietic cells. 
LT-HSC, long-term repopulating HSC; ST-HSC, short-term repopulating HSC; MPP, 
multipotent progenitor; CMP, common myeloid progenitor; CLP, common lymphoid 
progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte−macrophage 
progenitor. The encircled pluripotent population, LT-HSC, ST-HSC and MPP are Lin-, 
Sca-1+, c-kit+ as shown. 
 
Reprinted with permission. Larsson J, Karlsson S. The role of Smad signaling in 
hematopoiesis. Oncogene. 2005;24(37):5676-5692.
12
 
  
 3 
the mouse embryo starts to make blood cells from E9.5 and was proven to be a powerful 
source of definitive HSCs.
10,11
 From E12.5 hematopoiesis switches to fetal liver and 
HSCs undergo dramatic expansion. Right before birth bone marrow becomes the major 
site of hematopoiesis through the whole life. (Figure 1-2) 
 
 
Hematopoietic Stem Cell 
 
HSCs are rare population and occur at a frequency of 1 stem cell in 10,000 to 
1,000,000 bone marrow cells. HSCs are derived from mesoderm and give rise to all the 
downstream progenitor cells and mature blood cells. Hemogenic endothelium hypothesis 
proposes that HSCs arise directly from committed endothelia cells (ECs) of the ventral 
aspect of the dorsal aorta in the AGM
13,14
 which is distinct from the hemangioblast 
hypothesis which supposes that a common bipotent precursor gives rise to both 
vasculature and the blood cells. Initial understanding of HSCs started with the discovery 
of CFU-S described by Till and McCulloch.
15
 They demonstrated that intravenously 
injected bone marrow cells were capable of forming distinct hematopoietic colonies in 
the spleen of irradiated mice, and these colonies contained erythrocytes, megakaryocytes 
an granulocytes/macrophages.
15
 Later studies pointed out there are at least two type of 
CFU-S: colonies that formed at day 8 after transplantation and those formed at day 
12.
16,17
 They are referred as day 8-CFU-S and day12-CFU-S. Cells residing in day8-
CFU-S were more committed progenitors with little or no self-renewal capacity and cells 
in day12-CFU-S contained certain self-renewing cells.
18
 Morrison and Weissman further 
confirmed that LT-HSC and ST-HSC can only be purified from day-12 to day-14 CFU-
S
1
. 
 
 
Functional characteristics of HSCs 
 
The functional characteristics of HCSs are self-renewal and multilineage 
differentiation potential. 
 
 
Self-renewal 
 
Self-renewal of HSCs is critical for HSC pool maintenance to prevent the 
exhaustion of blood formation. It is usually achieved by either symmetric or asymmetric 
cell division or both. Symmetric division will result in two identical daughter stem cells 
or two lineage-restricted progenitors while asymmetric division will generate one 
daughter stem cell and one differentiated cell
19. Asymmetric cell division doesn’t 
generate net increase of HSC numbers. Self-renewal potential of HSCs is associated with 
the activity of telomerase
20-22
. Telemetric shortening during cell division usually results 
in cell cycle arrest, chromosomal instability and replicative senescence and causes the 
loss of self-renewal capacity of HSCs which directly reduces HSC pool size.  
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Figure 1-2. Timeline of hematopoietic events in the mouse conceptus. 
Arrows above indicate the onset of specific hematopoietic cell generation and/or 
appearance; arrows below indicate the earliest time of colonization of the secondary 
hematopoietic territories. AGM, Aorto Gonado Mesonephros region. 
 
Reprinted with permission: Dzierzak E, Speck NA. Of lineage and legacy: the 
development of mammalian hematopoietic stem cells. Nat Immunol. 2008;9(2):129-
136.
23
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Multilineage differentiation potential 
 
Multilineage differentiation means HSCs are able to produce progeny that 
contribute to all blood cell lineages.
24-30
 The decision of HSCs to self-renew or 
differentiation may be random, but the external signals from bone marrow niche play role 
in the cell fate decision of HSCs during lineage commitment through cell-cell or cell-
extracellular matrix (ECM) interactions or through cytokines, chemokines or other 
extracellular molecules. Signaling pathways present in bone marrow niche, such as Wnt 
pathway and Notch pathway, act on HSCs or downstream progenitors to regulate HSC 
lineage commitment. Recent evidence showed multilineage priming is one mechanism 
how HSCs maintain multilineage commitment potential without changing global gene 
expression. Open chromatin structure of HSCs or multipotent progenitors leaves many 
key cis-acting regulatory elements of lineage-affiliated genes accessible which allows 
these genes to be available for transcription. Transcription factors which favor different 
lineage commitment may negatively interact with each other resulting in the dominant 
upregulation of a given program with the shutdown of other program consistent with 
dominant lineage selected. 
 
 
Hematopoietic stem cell characterization 
 
Murine HSCs are a rare population capable of reconstituting recipients and reside 
in fetal liver and adult BM. There are studies to characterize and purify hematopoietic 
stem cells for decades. It becomes clear that combination of surface markers/dye 
exclusion and in vivo/ex vivo functional assays is necessary to identify functional HSCs 
which are able to reconstitute lethally irradiated hosts. More defined subpopulations with 
distinct reconstitution capacity were identified with combination of newly discovered cell 
surface markers by many groups. Here we focus on the phonotypical and functional 
characterization of murine hematopoietic stem cells. 
 
 
Cell surface antigens/receptors 
 
In 1988 Weissman’s group first identified multilineage HSC as a highly enriched 
rare population in lineage marker negative (Lin
-
), Sca-1
+
 and thy1.1
low
 cells, which 
represent about 0.05% of the whole bone marrow.
27
 Ikuta, K et al
31
 showed that both 
HSCs and progenitors express Kit surface marker, but only Lin
-
c-Kit
+
Sca-1
+
 cells are 
primitive HSCs and response better to SCF and stromal cells.
32
 The flk-2 gene, a tyrosine 
kinase receptor, was shown not to be expressed in FR25 Lin
-
c-kt
BR
 population which is 
highly enriched for HSCs
33
 and flk-2 was characterized as HSC marker to further purify 
LT-HSC from adult bone marrow cells as c-Kit
+
Lin
-
Sca-1
+
Flk-2
-
 cells from mice.
2
 Flk-2 
can only be used to separate adult HSCs as fetal liver HSCs express Flk-2. CD34 is a 
human HSC marker.
34
 Unlike human HSCs, mouse long-term multilineage HSCs are 
present in CD34
lo/-
c-Kit
+
Sca-1
+
Lin
-
 fraction,
30
 providing a new marker to separate mouse 
HSCs at a near homogenous level, even though only 20% of intravenously injected 
CD34
lo/-
c-Kit
+
Sca-1
+
Lin
-
 cells conferred long-term multilineage reconstitution.
30
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However, in fetuses and neonates CD34 is also expressed in long-term repopulating 
HCSs.
35
 So using CD34
-
LSK as a marker to purify HSCs is only suitable for mice older 
than 10 weeks due to age-dependent CD34 expression in HSCs. More recently 
combination of SLAM family member CD150 and CD48 with Lineage marker, Sca-1 
and c-Kit was found to be able to purify more enriched functional long-term HCSs.
36
 One 
out every 2.1 CD150
+
CD48
-
Sca-1
+
Lin
-
c-Kit
+
 cells gave long-term multilineage 
reconstitution in lethally irradiated mice.
36
 
 
 
Dye exclusion 
 
Hoechst 33342
low
 side population (SP) is a small subset of population of murine 
bone marrow cells which is able to block the Hoechst efflux activity due to a multidrug 
resistance protein (mdr) or mdr-like mediated efflux. SP was shown to be enriched about 
1000 fold HSC activity and Hoechst 33342 was used to isolate quiescent and replicating 
HSCs.
37,38
 Similar to Hoechst33342, Rhodamine123 (Rh123) is another vital dye used to 
label relative more quiescent murine HSCs and Rh123
low 
 cells self-renew to a greater 
degree than Rh123
high
 population.
39
 Rh123
low
 and Hoechst33342
low 
population both 
represent G0/G1 HSCs with higher level of self-renewal and long-term multilineage 
reconstitution capacity, which were lost within S/G2/M subpopulation.
39
 Resistance to 
active DNA replication provided these quiescent HSCs the radioprotection activity.  
 
The phenotype of murine hematopoietic stem cells at different development 
stages is summarized in Table 1-1. 
 
 
Functional assay 
 
In vitro functional assays developed for HSCs are cobblestone area-forming cell 
(CAFC) assay and long-term culture-initiating cell (LTC-IC) assay. Actually they are not 
able to identify true HSCs; instead they are the assays identifying relative immature cells 
in culture. The first in vivo assay to assess HSC function is thought to be CFU-S
15
 until 
the cells forming spleen colonies were proven to be hematopoietic progenitors with short-
term potential.
18
 To test repopulating HSC function long-term transplantation assay is 
required. 
 
 
Long-term repopulating assay 
 
Long-term repopulating assay requires intravenous injection of test bone marrow 
cells to irradiated or compromised hosts. Test cells and host cells should be 
distinguishable from each other by different alleles of the hematopoietic cell marker 
CD45.1 or CD45.2. In earlier studies cells were distinguished by different hemoglobin
40
 
or gender.
41
 Peripheral blood (PB) is collected at various intervals and contribution of test 
cells to myeloid, T lymphoid and B lymphoid lineage are assessed by flow cytometry. 
LT-HSCs are considered to be present in test cells only when recipient PB contains  
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Table 1-1. Phenotype of murine hematopoietic stem cell at different development 
stage. 
 
HSC Marker 
Hemangioblast (Primitive streak, yolk 
sac) 
Flk-1(Kdr)
+
 
Pre-HSC (AGM) CD34
+
CD41
+
Sca-1
-
CD45
-
 
HSC (AGM, placenta) CD34
+
CD45
+
CD41
+/-
Sca-1
+/-
 
HSC (fetal liver) Sca-1
+
CD34
+
CD45
+
Mac1
+
CXCR4
+
 
HSC (bone marrow) c-kit
+
Thy1.1(CD90)
lo 
Lin-Sca
hi
 (KTLS) 
 Sca-1
+
CD34
+/-
CD45
+
Lin
-
 
 CD150
+
CD48
-
CD244
-
 (SLAM) 
 Rh123
low
, Hoe33342
low
,PyroninY
low
 
 5-FU resistant 
 Aldehyde dehydrogenase
high
 
Fr25 (Small cells) Lin
-
 
 Side-population cells 
AGM, aorta gonado mesonephros; 5-FU, fluorouracil; HSC, hematopoietic stem cell; 
SLAM, signaling lymphocyte activation molecule. 
 
Reprinted with permission. Ratajczak MZ. Phenotypic and functional characterization of 
hematopoietic stem cells. Curr Opin Hematol. 2008;15(4):293-300.
42
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donor- derived cells in the all triple lineages after at least 16 weeks post transplantation. 
Long-term repopulating assay also can be used to evaluate HSC activity in genome 
modified cells by retroviral delivery with fluorescence markers or leukemia-initiating 
cells (LICs) from leukemia samples. 
 
 
Competitive repopulation assay 
 
In competitive repopulation assay test cells and standard cells are mixed at variety 
of ratio, 1:1 ratio at most cases, and injected into hosts. Usually standard cells contain 
specific number of whole bone marrow cells or HSCs which allows semi-qualify HSC 
frequency relative to standard cells. Test cells and standard cells should be 
distinguishable from each other. For more accurate evaluation of competitive 
reconstitution unit (CRU) frequency limiting-dilution assay is used. 
 
 
Limiting-dilution assay 
 
Limiting-dilution assay allows evaluation of absolute CRU frequency (HSC 
number) in test cells. It involves a titration of varying dose of test cells (at least 3 doses), 
which are mixed with 1-2x10
5
 competitors (contain about 5-10 CRU) and injected into 
lethally irradiated hosts. Competitors are usually subjected to two rounds of bone marrow 
transplantation prior to the limiting-dilution assay. The proportion of recipients whose 
bone marrow cells are determined to contain >1% or >5% cells of test cell origin in all 
three lineages (myeloid lineage, T lymphocyte lineage and B lymphocyte lineage) after at 
least 16 weeks following transplantation is used to calculate the CRU frequency 
generated by Poisson statistics. 
 
 
Serial transplantation assay 
 
Given population is transplanted into primary recipients, whose bone marrow 
cells were harvested and transplanted into secondary recipients and further into tertiary 
recipients. Serial transplantation assay is the most stringent HSC assay since only the 
most primitive HSCs are able to yield long-term, multilineage repopulation through 
multiple rounds of transplantation. 
 
 
Regulation of Hematopoietic Stem Cell Pool 
 
HSCs give rise to all the blood lineages throughout the life span; as a result HSC 
pool should be well maintained. This usually involves the regulation of the balance of 
HSC self-renewal and differentiation, HSC survival and death (apoptosis/necropsies), 
lineage priming and selection and many other aspects of HSC activities by either intrinsic 
or extrinsic signals or both. Intrinsic mechanism includes transcription factors, epigenetic 
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modification, non-coding RNA, especially microRNA and extrinsic signals come from 
microenvironment (bone marrow niche) where HSCs reside.  
 
 
Transcription factors 
 
Numerous of transcription factors are shown to play critical role in HSC self-
renewal or differentiation through gain of function or loss of function assays. They 
include HOX genes, Gata2, Runx1, Gfi1 and many others. HOX genes are highly 
conserved from Drosophila to mammals and play roles in embryonic patterning and 
hematopoiesis. The detail of HOX gene function in normal and malignant hematopoiesis 
will be discussed in later paragraphs. Gata2 is one of the six members of GATA family 
in mammals. It is expressed in primitive hematopoietic cells and its expression level 
declines gradually along hematopoietic differentiation.
43,44
 Gata2 knock-out mice die at 
day 10-11 of gestation due to impaired primitive hematopoiesis, demonstrating that 
Gata2 is essential for earliest stage of hematopoiesis during embryogenesis.
43,44
 Gata2 is 
also crucial for adult HSCs and HPCs proliferation. Gata2 may preserve immature cell 
pool by inhibiting hematopoietic precursor cell differentiation and also confers increased 
quiescence of human HSCs and HPCs when expressed at high level.
45,46
 At meanwhile, 
reciprocal expression pattern of Gata1 and Gata2 is critical for erythropoiesis and 
erythroid homeostasis. Gata2 may function through SCL and active both Kit and Gata2 
in immature erythroid cells.
47
 
 
 
Epigenetic regulation 
 
Epigenetic regulation, histone or DNA modification, allows changes of large set 
of gene expression by influencing the accessibility of transcription factors to DNA and 
altering transcription profile of cells. Epigenetic regulation includes methylation, 
acetylation, phosphorylation, sumoylation and ubiquitylation. Here we focus on the 
discussion how histone or DNA epigenetic modification regulates or maintains HSC 
signature. 
 
Histone hyperacetylation usually indicates ‘open’ chromatin whereas 
deacetylation means ‘condensed’ chromatin. Histone acetylation is catalyzed by histone 
acetyl transferase and histone deacetylation is catalyzed by histone deacetlylases 
(HDACs). Histone methylation usually occurs on arginine or lysine residues. Methylation 
on H3K4, H3K36 and H379 are associated with transcription activation while 
methylation on H3K9, K3K27 and H4K20 are related to transcription repression. BMI1 
belongs to Polycomb-group (PcG) proteins, which repress gene (such as HOX genes) 
transcription through histone modification. Bmi-1
-/-
 mice demonstrated reduced number 
of adult HSCs but not fetal liver HSCs and defect in long-term reconstitution of both fetal 
liver and adult HSCs
48
 while enforced expression of Bmi-1 augments HSC self-
renewal,
49-51
 indicating Bmi-1 is essential for self-renewing HCSs. Besides HSCs, Bmi-1 
is also required for neuron stem cells self-renewal but not survival or differentiation.
52
 A 
similar phenomenon was observed in the Mph1/Rae28 loss mice
53
 and MPH1/RAE28 is 
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another member of PcG family which forms ploycomb complex 1 with M33, BMI1 or 
MEL18 and SCMH1.
54-58
 In contrast, Ring1b loss mice
59
 or mice with hypomorphic 
mutation of Eed
60
 or Suz12
61,62
 exhibited enhanced HSC or HPC activities. 
 
Methylation of CpG in DNA is another major epigenetic modification. DNA 
methylation is catalyzed by DNA methyltransferase (Dnmt1, Dnmt3a and Dnmt3b) and 
methylation in promoter region is associated with gene silencing. Dnmt3a and Dnmt3b 
execute de novo DNA methylation and play role in the regulation of cell differentiation. 
CD34
-
LSK cells express both Dnmt3a and Dnmt3b. Disruption of Dnmt3a or Dnmt3b or 
both do not affect either myeloid or lymphoid lineage differentiation potential while loss 
of both Dnmt3a and Dnmt3b but not either one of them result in defect in long-term HSC 
reconstitution.
63
 Later Challen et al
64
 applied serial transplantation on Dnmt3a-null HSCs 
which demonstrated 200-fold expansion of phenotypic HSCs in secondary recipients 
coupled with declined multi-lineage differentiation capacity with successive rounds of 
transplantation. Expansion of Dnmt3a-null HSCs was associated with activation of HSC 
self-renewal program including Runx1 and Gata3 indicating the essential role of Dnmt3a 
in silencing self-renewal genes in HSCs and permission of hematopoietic 
differentiation.
64
 Conditional knockout of Dnmt1 led to defects of HSC self-renewal, 
bone marrow niche retention and generation of myeloid-restricted progenitors from 
HSCs.
65
 Haploinsufficency of Dnmt1 was shown to be sufficient to impair self-renewal 
of MALL-AF9-induced leukemia stem cells (LSCs) and similar effect
66
 was seen in B-
Lymphoid leukemia with Dnmt1 hypomorphic allele.
67
 These studies indicated the role of 
Dnmt1 in normal and malignant HSCs for regulation of self-renewal.  
 
 
Signaling pathways 
 
 
Wnt signaling pathway 
 
Wnt signaling regulates both HSC self-renewal and differentiation. In mammals 
Wnt proteins are present in primitive and definitive hematopoiesis sites. Wnt-5a and 
Wnt-10b are expressed in murine yolk sac (E11), fetal liver (E14) and fetal liver HSCs.
68
 
In vitro culture Wnt-5a was shown to have positive effect on proliferation of fetal liver 
HSCs in an autocrine and paracrine manner, while monocyte and erythrocyte formation 
were preferred from bone marrow HPCs in the present of soluble Wnt-5a.
69
 
Overexpression of β-catenin, downstream executor of the Wnt signaling cascade, 
enhances HSC self-renewal.
70
 Β-catenin also has been shown to promote T-ALL cells 
survival, adhesion and proliferation, and it is undetectable in mature T cells.
71
 Whether β-
catenin shared the same mechanism on HSCs self-renewal and leukemic cells 
proliferation is not yet clear.  
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Notch signaling pathway 
 
Notch signaling requires physical interaction of Notch ligands and Notch 
receptors, which are expressed in Notch-ligand-expressing cells and Notch-expressing 
cells, separately. In bone marrow, HSCs express Notch and bone marrow stromal cells, 
endothelial cells and fibroblasts, express Notch ligands, such as Jagged and Delta. Notch 
signaling is critical for embryonic development as Jag1-deficient mice are embryonic 
lethal due to the defects in the vasculature remodeling.
72
 Notch signaling plays a role in 
modulating HSCs self-renewal, differentiation and proliferation. Jagged1 alone inhibited 
proliferation and myeloid colony formation of CD34
+
 cells but enhanced erythroid 
colony formation in the presence of stem cell factor (SCF).
73
 Activation of endogenous 
Notch signaling with immobilized Delta-1enhanced proliferation of cord blood derived- 
CD34
+
 cells in vitro and myeloid-lymphoid repopulating ability in vivo.
74
 Expression of 
the intracellular domain of Notch 1 can immortalized murine HSCs and immortalized cell 
line was able to differentiate into both myeloid and lymphoid lineages.
75
 
 
 
Phosphatidylinositol 3 kinase pathway 
 
Phosphatidylinositol 3 kinase pathway (PI-3) kinase pathway promotes cell 
growth, proliferation and survival. PI-3 kinase can be activated by receptor tyrosine 
kinase or other signaling pathway and generate Phosphatidylinositol-3, 4, 5-trisphosphate 
(PIP3). PIP3 further activates Art. Phosphorated Akt activates mammalian target of 
rapamycine (mTOR) kinase. mTOR1 promotes cell growth and proliferation, while 
mTOR2 regulates Akt activity. Pten negatively regulates PI-3 kinase pathway by 
dephosphorylating PIP3, thus resulting in inhibition of cell growth, proliferation and 
survival. Conditional knock-out of Pten from embryonic stem cells as well as neuron 
stem cells can drive cells into cell cycle and enhance self-renewal.
76-78
 Deletion of Pten 
from adult HSCs also increase cell cycle entry, leading to transient increase of HSC 
numbers but depletion of HSCs in the mouse bone marrow in the end.
79,80
 Phenotype of 
Pten deletion/inactivation demonstrated that Pten normally maintains HSCs in a quiescent 
state. However, Pten deletion also drives leukemogenesis. Yilmaz reported 
myeloproliferative disease which progressed to AML and ALL when Pten was 
inactivated in murine hematopoietic system using flox-Mx-1-Cre system.
79
 Different role 
of Pten deletion on HSCs depletion and leukemic stem cells generation suggests 
independent mechanism of each phenomena caused by Pten inactivation. 
 
 
TGF/BMP signaling pathway 
 
TGF-β superfamily includes TGF-β/activin/nodal family, bone morphogenetic 
protein (BMP)/growth and differentiation factor (GDF)/Muellerian inhibiting substance 
(MIS) family. Upon binding of the ligands, activated type I and type II serine/threonine 
kinase receptors form heterodimer and phosphorylate specific intracellular receptor-
regulated Smads (R-Smad), including Smad1,2,3,5,and 8. Smad1, Smad5 and Smad8 are 
primary mediators of BMP signaling, while Smad2 and Smad3 transduce signal through 
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TGF-β/activin receptors. Dimer of R-Smads forms complex with common partner, Smad-
4, and translocates into nucleus to transcriptionally regulate various target genes in a cell-
specific and ligand-dose dependent manner. Inhibitory Smads (I-Smad), Smad6 and 
Smad7, can negatively regulate TGF-β signaling pathway by interfering R-Smads and 
receptor or R-Smads and Smad4 interaction or recruiting E3-ubiquitin ligases to degrade 
receptors. Smad1 belongs to BMP signaling pathway. Many studies showed that BMP4 
plays a key role in mesoderm induction and hematopoietic commitment and BMP4 
knock-out mice displayed defects in mesoderm and blood island formation.
81
 For adult 
HSCs, BMP4 may act as positive regulator of proliferation and survival. High 
concentration treatment of BMP4 to human HSCs in vitro can enhance its engraftment in 
nonobese diabetic-severe immunodeficiency (NOD/SCID) mice.
82
 At meanwhile, BMP4 
signaling is also important in sonic hedgehog (SHH)-induced human progenitor 
proliferation.
83
 Different from BMP4, TGF-β1 ligand-activated TFG-β signaling inhibits 
HSCs proliferation and induces HSCs apoptosis in vitro. In vivo injection of TGF-β1 also 
inhibits proliferation of murine multipotent hematopoietic progenitors in bone marrow.
84
 
As negative regulator of TGF-β signaling, Smad7 is able to block all TGF-β signaling 
pathways. Overexpression of Smad7 increases HSCs repopulating activity in serial 
transplantation setting.
85
 Increased proliferation induced by Smad7 was not seen in 
culture. This suggests signaling crosstalk between bone marrow cell and bone marrow 
niche is required for Smad7 to increase HSCs self-renewal. 
 
 
MicroRNAs 
 
MicroRNAs are small, noncoding RNAs which regulate gene expression through 
transcription or translation repression by interfering initiation of transcription or mRNA 
destabilization. Dicer is an enzyme which cleaves double-stranded RNA (dsRNA) and 
pre-microRNA (pre-miRNA) into small interfering RNA or and microRNA respectively. 
Conditional deletion of Dicer led to loss of HSPCs due to significant increased apoptosis, 
indirectly suggesting the role of microRNA in HSC maintenance.
86
 Several microRNAs 
including Mir-125a, Mir-125b, Mir-126, Mir-130 and Mir-155, are highly enriched in 
HSCs
86-90
 and dysregulation of some microRNAs are associated with human 
hematopoietic malignancies such as MDS/AML,
91
 B-cell acute lymphoblastic 
leukemia
92,93
 and chronic lymphocytic leukemia (CLL).
94
 miR-99b/let7e/miR-125a 
cluster is highly expressed in LT-HSCs and overexpression of miR-99b-let7e-miR-125a 
cluster or miR-125a alone was able to enhance HSC long-term multilineage 
reconstitution.
86
 When overexpressed separately, only miR125a but not miR-99b, let7e 
was able to amplify HSC pool size in vivo by protecting primitive hematopoietic cells 
from apoptosis through downregulation of proapoptotic protein Bak1.
86
 MiR-125b is 
another microRNA highly expressed in LSK cells. Overexpression of miR-125b 
demonstrated reconstitution advantage at competitive transplantation setting but caused a 
dose-dependent myeloproliferative disorder/myeloid leukemia.
89
 The observation of miR-
125b-induced HSCs expansion was confirmed in Ooi. A,G et al’s study, but they further 
identified that miR-125b preferentially expanded Slamf1
lo
CD34
−
LSK lymphoid-balanced 
and the Slamf1
neg
CD34
−
LSK lymphoid-biased cell, possessing a balanced 
myeloid/lymphoid and lymphoid-biased cell output, respectively.
88
 Besides the regulation 
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of HSC self-renewal, many microRNAs were implicated in regulating hematopoietic 
progenitor cells (HPCs) differentiation, including miR-155 for lymphoid and myeloid 
development,
87,95,96
 mir-233 for myeloid differentiation
97,98
 and the miR-181/miR-
150/miR-17-92 cluster for lymphoid differentiation.
99-102
 Taken together, microRNAs 
regulate hematopoiesis at multiple levels including HSC self-renewal, HSC fate decision 
and HPC differentiation.  
 
 
HOX Gene Family 
 
HOX genes are homeodomain-containing transcription factors. They were 
initially characterized in Drosophila and involved in process of body pattern during the 
embryo development as well as many adult processes including hematopoiesis. Hox gene 
products share evolutionally conserved 60-amino-acid homeobox domain, which 
specifies basic Helix-turn-helix DNA binding domain. Sequences flanking the 
homeodomain have been shown to have either activation or suppression functions. In 
Drosophila the HOX genes map to the antennapedia complex (Ant-C) and Bithorax 
complex (BX-C), which are referred to HOM-C.
103-105
 Antp class genes include labial 
(lab), proboscipedia (pb), Deformed (Dfd), Sex combs reduced (Scr), Antennapedia 
(Antp), Ultrabithorax (Ubx) and abdominal-A (abd-A) (Figure 1-3). Abdominal-B (Abd-
B) is another homeotic selector gene and it is related to Antp class by its sequence but not 
structure. Lab, the most 3’ gene is required for the most anterior HOM-C functional 
domain while the most 5’ gene of the complex, Abd-B, is required for the posterior 
abdominal segment development. In human and murine genomes there are 39 class I Hox 
genes due to genome duplication. They are referred to HOXA, HOXB, HOXC, and 
HOXD clusters, each of which contains 9 to 11 groups located on human chromosomes 
7, 17, 12 and 2 or mouse chromosome 6, 11, 15 and 2 (Figure 1-3).
96,97
 In mammals Hox 
genes carrying the same number in different clusters are paralogous and the paralogy is 
complete only in groups 13, 9, and 4, which contain all four genes. All Hox genes have 
the same 3’-to-5’orientation and according to their position within their respective gene 
cluster 3’ Hox genes are expressed early on and at anterior locations whileas 5’ Hox 
genes are expressed later developmental stage and at posterior locations during the 
development. The correspondence between gene topology and the place and time of 
transcription are referred to as spatial and temporal collinearities, respectively. 
 
 
HOX gene upstream regulators 
 
Retinoic acid, Trithorax group (Trx-G) and Polycomb group (PcG) genes were 
shown to be upstream regulators of HOX genes in hematopoietic and non-hematopoietic 
tissues. Due to lack of the evidence showing that retinoic acid treatment regulates HOX 
gene expression in hematopoietic cells, here we focus Trx-G and PcG genes. 
 
Trithorax is required for the maintenance of HOM-C genes expression in the 
Drosophila.
106
 Mixed lineage leukemia (MLL) is the mammalian homolog of Trithorax 
gene and is usually seen as part of fusion genes in leukemia such as infant biphenotypic 
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Figure 1-3. A schematic structure of clustered HOX genes. 
The 39 HOX genes are located on four different chromosomes. Homology of human 
HOX genes HOX-C to Drosophila HOM-C genes is shown by colors. Blank squares 
show missing genes.They play critical role in body patterning during embryo 
development. 
 
Reprinted with permission. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of 
HOX genes in normal hematopoiesis and acute leukemia. Leukemia. 2013;27(5):1000-
1008.
107
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leukemia
108
 and etoposide-induced leukemia.
109
 Mll-null mice are embryonic lethal due 
to morphogenetic defects and hematopoietic abnormality.
110
 Disrupted Hox gene 
expression pattern along the vertebral axis due to loss of Mll was also observed.
110
 Mll-
null fetal liver HPCs showed reduced colony forming capacity and it can be due to the 
effect of loss of Mll or disrupted downstream HOX genes on the growth of hematopoietic 
precursors.
111
 
 
As mentioned in previous paragraph PcG proteins maintain HOX genes in a 
repressed status through histone modification. PcG genes are preferentially expressed in 
differentiated bone marrow cells except Bmi-1,
112
 which is consistent with their role in 
repressing HOX gene expression. Bmi-1 and Mph1/Rae28 are two well-studied PcG 
genes regarding their roles in hematopoiesis and these studies were discussed in previous 
section. 
 
 
Hox cofactors 
 
Homeodomain HOX proteins recognize and bind to specific TAAT DNA 
consensus site which confers HOX genes limited specificity. HOX proteins cooperatively 
bind to DNA with PBC, a group of three animo acid loop extension (TALE) 
homeodomain-containing proteins. PBC gene family includes the pre-B-cell leukemia-1 
(Pbx-1) and myeloid ectopic insertion site (Meis) families.
113-116
. HOX cofactors provide 
further specificity and affinity of HOX proteins. PBX proteins do not have strong protein-
DNA interaction, but they are able to form protein complex with HOX proteins from 
paralog group 1 to 10, thus providing DNA-binding specificity of HOX proteins from 
different paralog groups.
116,117
 HOX proteins from paralogs 1 to 8 form protein complex 
with PBX through a tryptophan within a conserved YPWM motif
118-121
 while HOX 
proteins from paralogs 9 to 10 utilize the tryptophan in a conserved ANW domain.
121
 
HOX proteins which belong to paralogs 11-13 prefer to form complex with MEIS1 
homeodomain proteins other than PBX,
121,122
 which was frequently detected in the 
leukemia arising in BXH2 mice.
123
 However, dimeric complex of MEIS/MEIS-like 
protein and PBX
124-129
 and trimeric complex of MEIS/MEIS-like protein-PBX-
HOX/HOX-like protein
128-130
 were also formed in myeloid leukemia cell lines or non-
hematopoietic tissues. 
 
 
Role of Hox genes in normal hematopoiesis 
 
HOX genes are expressed in HSCs and progenitors in a lineage-specific or 
differentiation stage-specific manner. Genes of HOXA clusters are more likely expressed 
in myeloid cells, HOXB genes in erythroid lineage and HOXC genes in lymphoid cells. 
HOXD genes play roles in limb development during embryogenesis but not in 
hematopoiesis since lack of expression of HOXD gene in hematopoietic cells.
131-133
 
Anterior 3’ end HOX genes including HOX1-6 are highly expressed in primitive HSCs 
and are downregulated along the differentiation while posterior 5’ end HOX genes are 
mostly expressed in committed hematopoietic cells.
134
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Evidence has been provided by the loss of function and gain of function studies of 
Hox genes in mouse models. HOX genes are actively involved in both embryonic and 
adult hematopoiesis, maintaining or enhancing HSC self-renewal as well as blocking or 
facilitating myeloid/lymphoid lineage differentiation (Table 1-2). Due to genetic 
interactions between HOX clusters, results of knockdown or knockout studies sometimes 
do not reflect the findings of overexpression studies. 
 
Knockdown of human HOXA5 in hematopoietic organs led to increased erythroid 
progenitor number and reduced myelomonocytic cells, while constitutive expression of 
HOXA5 increased myeloid progenitor numbers and blocked erythroid 
differentiation.
135,136
 Hoxa7 null mice displayed reduced megakaryocyte/erythroid 
progenitors with reticulocytosis and thrombocytopenis, suggesting a role in 
megakaryocyte and erythrocyte development.
137
 Knockout Hoxa9 caused more severe 
phenotype than Hoxa7. Hoxa9 null mice displayed reduced lymphoid and myeloid cells 
together with reduction in CLPs, CMPs and GMPs.
137
 Though aberrant expression of 
Hoxa7 and Hoxa9 is the feature of leukemia harboring MLL mutations, Hoxa7
 
and 
Hoxa9 are not necessary for MLL-GSA7-mediated leukemogenesis.
137
 Overexpression of 
Hoxa9 increased HSC and myeloid progenitor pools and reduced pro-B progenitors.
138
 
and further led to myeloid leukemia with long latency through collaboration with 
MEIS1a but not PBX1b.
139
 Similar to Hoxa9, Hoxa10 was identified as pro-oncogenic 
gene which can lead to increased myeloid blast cells in vitro, blocked erythroid 
differentiation in methylcellulose, reduced B cell differentiation and enhanced 
myelopoeisis in vivo when overexpressed in human purified CD34
+
 hematopoietic 
progenitor cells.
140
 HOXB4 was shown to be one of the most promising factors which 
can expand murine HSC in vitro and in vivo without compromising HSC multilineage 
differentiation potential at a dose-dependent manner.
141
 However Hoxb4 knock-out 
studies showed lacking entire Hoxb4 gene had little effect on hematopoiesis, with mild 
reduction in the number of HPCs and HSCs in adult bone marrow and fetal liver without 
multilineage differentiation perturbation.
32
 Other Hoxb genes were shown to be expressed 
at 2.3-3.6 fold higher level in c-Kit
+
 fetal liver  cells of Hoxb4 null mice, while the 
expression level of Hoxb4 paralogs were not altered (Hoxa4, Hoxd4) or even reduced 
(Hoxc4),
142
 suggesting other Hoxb genes’ but not Hoxb4’s paralogs’ duplicate roles in 
hematopoiesis in Hoxb4 null mice. Biji
142
 et al also showed that loss of the Hoxb entire 
cluster had little effect on murine fetal liver HSC self-renewal and differentiation 
potential. c-Kit
+ 
fetal liver cells from Hoxb1
-
Hoxb9
-/- 
demonstrated downregluation of 
almost all Hoxa genes expect Hoxa13, upregulation of Hoxc4, Hoxc9 and Hoxc11,
142
 
indicative a complex network of genetic interaction between Hox genes in hematopoietic 
cells. Roles of Hoxb3, Hoxb6, Hoxc3, HOXC4 and Hoxc8 in HSC maintenance and 
myeloid, lymphoid and erythroid differentiation were elaborately described in many other 
studies.
143-149
 
 
 
Role of Hox genes in acute leukemia 
 
Though Hox genes were showed to play roles in normal hematopoiesis, numerous 
studies have shown that aberrant expression of some HOX genes are highly associated
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Table 1-2. HOX gene studies. 
 
HOX gene Gain of function Loss of function Species Reference 
HOXA5 
↑Myeloid progenitors and block erythroid 
differentiation. 
↑Erythroid progenitors and 
↓myelomonocytic cells. 
Human 
135,136
 
Hoxa7  
↓MEP, reticulocytosis and 
thrombocytopenia. 
Mouse 
137
 
Hoxa9 
↑HSCs expansion and myeloid progenitor 
proliferation. Block erythroid 
differentiation and ↓pre-B-cell 
differentiation. 
↓↓CMP, GMP, CLP, lymphoid 
precursors, repopulating ability 
and ↓ spleen cellularity and size. 
Mouse 
137-139,150
 
HOXA10 
↑↑ Blasts cells and myelopoiesis, ↓B-cell 
differentiation and block erythroid 
differentiation 
 Human 
140
 
Hoxb3 
Block B and T-cell differentiation and a 
delay in myeloid precursor proliferation. 
↓↓ B-cell progenitors and BM 
cellularity. 
Mouse 
143,144
 
HOXB4/hoxb4 ↑↑HSCs expansion. 
↓↓Hematopoietic organs 
cellularity and size, ↓ HSCs and 
HPs and ↑Hoxb genes. 
Human/
Mouse 
141,142,151,152
 
Hoxb3/b4  ↓↓ HSCs and HPs Mouse 153 
Hoxb6 
↑HSCs expansion and myeloid precursor 
proliferation. ↓Erythropoiesis and 
lymphopoiesis 
↑Early erythroid progenitors. Mouse 146,147 
Hoxc3  ↓Erythroid progenitors. Mouse 149 
HOXC4 
↑Early and committed myeloid and 
erythroid progenitors. 
 Human 
148
 
Hoxc8  
↓↓Erythroid, granulocytes and 
marcrophage colony formation 
potential. 
Mouse 
145
 
 18 
Table 1-2. (Continued). 
 
Abbreviations: CLP, common lymphoid precursors; CMP, common myeloid progenitors; GMP, granulocyte/monocyte precursors; 
HOX, homeobox; HP, Hematopoietic progenitors; HSCs, Hematopoietic stem cells; MEP, megakaryocytic/erythroid progenitors. 
 
Reprinted with permission. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in normal hematopoiesis and 
acute leukemia. Leukemia. 2013;27(5):1000-1008.
107
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with hematopoietic malignancies through forming HOX fusion proteins, dysregulation by 
their upstream regulators or other factors. 
 
Since NUP89-HOXA9 fusion protein was identified in t(7;11)(p15;p15) positive 
human myeloid leukemia
154,155
 due to chromosome translocation, many other HOX genes 
have been shown to be NUP98 translocation partners including HOXA11,
156,157
 
HOXA13,
156
 HOXD11,
158
 HOXD13
159
 and HOXC11
160
 in human acute myelogenous 
leukemia (AML) and T-cell acute lymphocytic leukemia (T-ALL). NUP98 is a nuclear 
pore complex protein and in NUP98 fusions N-terminal GLFG repeats of NUP98 gene 
joins the C-terminal portion of HOX genes including homeodomain. NUP98 fragment 
may lead HOX protein to bind to inappropriate target genes or dysregulate HOX target 
gene expression. Retroviral delivery of NUP98-HOX fusion genes were proved to cause 
myeloproliferative disease or AML in transplanted mice.
161-163
 Co-expression of MEIS1 
can shorten the latency of NUP98-HOXA9-mediated AML in transplanted mice from 
230 days to 142 days
163
 and induce myeloblastic leukemia together with NUP98-
HOXD13 fusion gene with latency of 75 days which was not seen in mice transplant with 
cells only transduced with NUP98-HOXD13 alone.
162
 Combination of NUP98-HOXA9 
and BCR-ABL or TEL-PDGFβR induced AML in transplanted mice which can’t be 
induced by NUP98-HOXA9 alone or BCR-ABL alone or TEL-PDGFβR alone.164 
 
Aberrant expression of HOX gene without chromosome translocation was also 
actively involved in hematopoietic malignancies including AML and acute lymphoid 
leukemia (ALL). It is usually caused by HOX gene upstream regulator. MLL maintains 
HOX gene expression by direct binding to the proximal promoter.
165
 Oncogenic MLL 
fusion proteins activate their transcriptional target at higher level than wild-type MLL
166
 
and usually upregulate 5’ end Hoxa genes other than 3’ end Hoxa genes in mouse 
immortalized cell lines in combination of Meis1.
167
 Earlier studies indicated expression of 
Hoxa genes and Meis1 was required for MLL fusion proteins transforming activity,
167
 but 
there are evidence showing involvement of Hoxa genes and Mesi1 varies in different 
MLL fusion protein-induced leukemias. MLL-ENL and MLL-CBP were not able to 
transform hematopoietic cells in Hoxa9 and Hoxa7 null background
167,168
 while Hoxa7 
and Hoxa9 do not contribute to the initiation of MLL-GAS7- and MLL-AF9-mediated 
leukemogenesis in mice.
137,169
 The possibility is that non-Hox gene targets of MLL fusion 
protein are sufficient to induce leukemias in mice, thus Hoxa9 or Hoxa7 are not long 
required for these MLL fusion protein-mediated leukemogenesis. CDX2 gene is another 
HOX gene upstream regulator which is highly expressed in 90% of human AML cases in 
the form of either wild-type CDX2 or ETV-fused CDX2. Overexpression of Cdx2 alone is 
sufficient to upregulate Hox genes, Hoxb3, Hoxb6, and Hoxb8 or Hoxb9, Hoxa10, Hoxb5, 
and Hoxa7, in mouse myeloid progenitors.
170
 CDX2 transforming actively is dependent 
on its N-terminal transactivation domain, which critical for CDX2 to dysregulate Hox 
gene expression.
170
 Nucleophosmin 1 (NPM1) is the protein located in nucleolus and can 
be translocated into nucleoplasm during serum starvation or anticancer drug treatment. 
Normal NPM1 dosen’t regulate HOX gene expression. Relocation of NPM1 into 
cytoplasm (NMPc
+
) upregulates a set of HOX genes in AML cases.
171,172
 But the 
molecular association of NPMc
+
 and dysregulation of HOX genes is not yet clear. 
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HOXB4 
 
HOX family members play an important role in body patterning during 
embryogenesis and demonstrated lineage-specific function through life in variety of 
tissues including the hematopoietic organs.
173
 In hematopoietic organs Hoxb4 is 
expressed in mouse Lin
-
Sca1
+
c-kit
+ 
(LSK) cells with long-term repopulating capacity and 
AGM-derive CD45
+
CD144
+
 cells which are enriched with HSCs.
174
 With undetectable 
Hoxb4 expression level in fetal liver HSCs Hoxb4 may not be critical for expansion of 
fetal liver HSCs.
174
 Hoxb4 expression undergoes down-regulation with hematopoietic 
differentiation. Specific expression of HOXB4 in HSCs suggests HOXB4’s important 
role in HSC self-renewal. However, loss of Hoxb4 studies revealed mild phenotype 
which seems to contradict to the observation from HOXB4 overexpression studies. 
Hoxb4-deficient mice had mild reduction in HSC numbers in both bone marrow and fetal 
liver without altering cell cycle distribution and compromised competitive repopulating 
capacity observed in both primary and secondary recipients.
152
 Moderate phenotype seen 
in Hoxb4-deficient mice may be due to compensation effect from other Hox genes. Or it 
suggests Hoxb4 plays less prominent role in non-stressed status of hematopoiesis and 
enhances proliferative rate of HSCs in the transplantation setting which demands higher 
level of proliferation. 
 
 
HOXB4 role in embryonic stem cell derived hematopoiesis 
 
Hoxb4 is selectively expressed in murine AGM-derived HSCs but not fetal liver 
HSCs, indicating Hoxb4’s role in HSCs specification but not amplification during 
embryogenesis. Cheryl D. Helgason et al
175
 showed overexpression of HOXB4 enhanced 
erythropoieitic and primitive hematopoietic differentiation potential of mouse ESCs with 
increased number of erythroid colony-forming (CFC-E) progenitors and mixed-lineage 
(granulocyte/erythroid/macrophage/megakaryocyte) colony-forming (CFC-GEMM) 
progenitors in culture. Later on George Daley’s group demonstrated that enforced 
expression of HOXB4 promoted murine embryonic body (EB)-derived CFU-GEMM 
formation which expressed HSC markers (c-Kit and CD31) and differentiation markers 
of myeloid, lymphoid and erythroid lineages and conferred cells isolated precirculation 
murine yolk sac as well as EB-derived hematopoietic cells with myeloid and lymphoid 
engraftment potential in lethally irradiated mice.
176
 Similar results were also observed by 
other groups.
177
 When it comes to human ESCs, HOXB4 overexpression by vector 
transfection and direct delivery of recombinant HOXB4 fusion protein also exhibited the 
similar outcome on human ESCs, leading to expansion of erythroid and 
myeloid/monocytic progenitors in culture.
178,179,180
 
 
 
HOXB4 overexpression enhances adult HSC self-renewal 
 
Keith Humphries’s group showed that overexpression of HOXB4 in murine 
primitive bone marrow cells by retroviral gene delivery significantly increased CRU 
frequency in lethally irradiated mice, achieving 1.4 fold increase above normal bone 
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marrow values while control cells only led to 3% recovery of normal value.
141
 Further 
studies showed HOXB4-transduced HSCs did not expand above normal HSC levels of 
unmanipulated mice in extended observation,
181,182
 indicating there were counter-
regulatory signals to regulate HOXB4-mediated HSC expansion in transplanted mice. 
Besides in vivo expansion of HSCs in transplanted mice, HOXB4 overexpressing HSCs 
were able to achieve 40-fold net HSC increase in vitro and retain lymphoid-myeloid 
repopulating potential.
183
 Both retroviral transfer of HOXB4 cDNA and direct delivery of 
the HOXB4 homeoprotein demonstrated certain level of expansion of human LTC-ICs 
and NOD-SCID mouse repopulating cells from human cord blood CD34
+
 cells.
151,184
 
Later on Xiao-Bing et al
185
 claimed species-specific differences in the potency of 
HOXB4-mediated HSC expansion which was highly dependent on HOXB4 expression 
level. HOXB4 expanded canine and mouse CD34
+ 
cells best and had the least efficiency 
on human or nonhuman primate CD34
+
 cells in vitro.
185
 Immortalized mouse 
hematopoietic cells by HOXB4 maintained short-term and long-term repopulating 
capacity without developing leukemia.
185
 HOXB4 protein is subjected to CUL4-mediated 
degradation and degradation-resistant HOXB4 markedly enhanced human CD34
+
 cells 
maintenance in vitro and in transplanted NOD/SCID/IL2R-γnull (NSG) mice with 
multilineage engraftment.
186
 
 
 
HOXB4 role in leukemogenesis 
 
It is believed that overexpression of HOXB4 enhanced murine HSC expansion in 
vitro and in vivo without causing hematopoietic disorders or malignancies.
141,181-183
 
Compared with other oncogenic HOX proteins,
139,143,147,162-164
 HOXB4 was considered as 
the most optimal factor to expand HSCs till recent report which described two cases of 
myeloid leukemias in HOXB4 transplanted large animals.
187
 Primitive status of the 
leukemia cells was dependent on the sustained HOXB4 expression, indicating HOXB4 
overexpression played a key role in the leukemic transformation in these large animals.
187
 
Integration site determined by LAM-PCR and activation of integration site nearby genes, 
PRDM16 and MYB, raised the possibility that gamma retrovirus integration-induced 
mutagenesis was involved in the leukemogenesis in the three large animals.
187
 So far this 
is the only report of HOXB4-associated AML and it may due to high level of the HOXB4 
expression achieved in the transplanted CD34
+
 cells. 
 
 
Prdm Gene Family  
 
PRDM (PRDI-BF1 and RIZ homology domain containing) family is a subfamily 
of the SET domain containing proteins and consists of 16 orthologs in rodents.
188
 They 
are all characterized by a N-terminal PR domain which is 20-30% identical to the SET 
domain present in histone lysine methyltransferase (HMTs) (Figure 1-4).
189
 PR domain 
is present in all family members and is followed by repeated zinc fingers except 
PRDM11 (Figure 1-5).
189
 Although most PRDM proteins contain PR domains, HMT 
activity was only detected in the PR domains of PRDM2, PRDM8 and PRDM9.
190-192
 
PRDM2 and PRDM8 were reported as repressive di-methylation of lysine9 of histone  
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Figure 1-4. The domain structure of the mouse PRDM1–16 proteins. 
Illustrations of the protein domain structure of the PRDM family members 1–16. These 
illustrations are drawn to scale based on a sequence analysis. Zinc fingers are represented 
by blue boxes and the PR domain by a red box. Those proteins for which a nervous 
system specific expression pattern is reported in this study are indicated with asterisks. 
 
Reprinted with permission. Kinameri E, Inoue T, Aruga J, et al. Prdm proto-oncogene 
transcription factor family expression and interaction with the Notch-Hes pathway in 
mouse neurogenesis. PLoS One. 2008;3(12):e3859.
189
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Figure 1-5. Structural and regulatory features of PRDM16. 
(A) PRDM16 domain structure and binding sites. After the N-terminal PR domain, the 
protein has a zinc finger DNA binding domain, a proline-rich domain, a repressor 
domain, another zinc finger DNA-binding domain, and a C-terminal acidic domain. The 
PR region corresponds to a SET domain, an 130-amino acid, evolutionarily conserved 
sequence motif with histone methyltransferase activity. The ten zinc finger domains 
correspond to the classical C2H2-type, in which the first pair of zinc-coordinating 
residues are cysteines, and the second pair are histidines, conferring zinc-dependent 
DNA- or RNA-binding properties. Two regions in PRDM16, namely zinc-finger (ZF)1 
and ZF2, have been identified to bind to PPARg, whereas C-terminal-binding proteins 
(CtBPs) have been shown to bind to a PLDLS motif at. (B) Schematic representation of 
brown adipocyte determination by PRDM16 
 
Reprinted with permission. Fruhbeck G, Sesma P, Burrell MA. PRDM16: the 
interconvertible adipo-myocyte switch. Trends Cell Biol. 2009;19(4):141-146.
193
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H3 (H3K9me2) HMTases
191,194
 while PRDM9 as activating tri-methylation of lysine4 of 
histone H3 (H3K4me3) HMTases.
192
 Other PRDM proteins without intrinsic 
methyltransferase activity recruit histone-modifying enzymes to achieve epigenetic 
regulation of gene expression, including HMTs, PRMT5 (Protein methyltransferase 5), 
LSD1 (lysine-specific demethylase1, Kdm1a), histone deacetylase (HDACs) and histone 
acetyltransferase (HATs) p300/CBP and P/CAF, by forming protein complex or through 
their own zinc figure domains or proline-rich domains. Besides histone-modifying 
enzymes, PRDM proteins also recruit histone-modifying enzyme-associated co-
repressors. CtBP (C-terminal binding protein) is one of the co-repressors frequently 
bound by PRDM2, PRDM3 and PRDM16 though their PLDLS CtBP-binding sites.
195-201
 
PRDM protein also can bind to DNA directly through their zinc finger domains. Zinc 
fingers of PRDM1 are able to recognize specific DNA binding sequence GAAAG and 
mediate PRDM1-DNA interaction.
202
 PRDM3 contains two zinc finger domains: the N-
terminal zinc fingers and C-terminal zinc fingers (Figure 1-4). N-terminal zinc fingers 
prefer to bind a GATA-like motif further from transcription start site (TSS)
203
 and C-
terminal zinc fingers bind an ETS-like sequence which is close to TSS.
204
 These two 
binding patterns of PRDM3 are exclusive to each other which means PRDM3 only binds 
to either of these two motifs, but not to both at the same promoter. In summary PRDM 
proteins regulate gene expression as HMTs or through recruiting other HMTs or direct 
bind to gene expression regulatory elements. Forming complex with a wide range of 
different HMTs or selective target binding sites provide Prdm proteins a context-
depended regulation activity. 
 
PRDM proteins play roles in normal tissue specification as well as cancer and 
other diseases. PRDM1 is primarily identified as transcription repressor and it maintains 
photoreceptor identity and neonatal enterocyte by repressing alternative differentiation 
programs.
205-209
 Even more PRDM1directs and maintains mast cell differentiation 
through maintaining other differentiation initiation at a repressive state.
210
 During plasma 
cell differentiation PRDM1 directly represses Myc through recruitment of HDACs
211
 and 
represses Ciita through LSD1.
212
 PAX5 and BCL6, both are required for B cell fate 
specification, are downregulated by PRDM1 during plasma cell differentiation. RNAi 
targeting Prdm16
213,214
 and Prdm16 mutant studies
214
 demonstrated that Prdm16 is 
essential for brown adipose tissue (BAT) maturation by preventing skeletal myocytes re-
specification and white adipose (WAT) tissue differentiation. Enforced expression of 
Prdm16 induced brown adipogenesis from myoblasts by activating PPARγ 
transcriptional function through direct protein-protein interaction.
214
 Many PRDM 
proteins also play roles in primordial germ cells and hematopoietic stem cells. The fact 
that certain cancer cells share the self-renewal machinery with normal stem cells 
indicates dysregulation of PRDM may be involved in tumorigenesis. Prdm3 and Prdm16 
maintain long-term and short-term hematopoietic cells.
215-218
 However, both PRDM3 and 
PRDM16 were original identified in acute myeloid leukemias. Expression of PRDM3 and 
PRDM16 that lack partial PR domain leads to myeloid leukemia and adult T-cell 
leukemia due to chromosome translocation events or viral vector insertional 
activation.
219-227
 Prdm1 and Prdm14 are essential for pluripotent primordial germ cells 
(PGCs) generation and Prdm1 mutants and Prdm14 mutants were not able to generate 
PGCs.
228-231
 Prdm14 is also required to maintain mouse ESCs at pluripotent state even 
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though Prdm14 is not required for mouse ESC derivation. Knockdown of Prdm14 in 
mouse ESCs led to downregulation of ESC genes and activation of extraembryonic 
endoderm program.
232-234
 Aberrant expression of PRDM14 was detected in breast cancer 
due to gene amplification on chromosome 8q13
235
 and human lymphoid neoplasms. Gain  
of function assay of Prdm14 in transplanted mice provided the evidence of the 
association of Prdm14 with lymphoid leukemia initiation in vivo.
236
 
 
 
PRDM16 protein domain 
 
PRDM16, which is also named as MEL1 (MDS1/EVI1 like gene 1), was first 
characterized from t(1;3)(p36;q21)-positive MDS/AML patient leukemia cells.
237
 MEL1 
is highly homologous to MDS1/EVI1 with first 222 amino acid sequence homologous to 
the PR domain of MDS1 and remaining sequence homologous to the EVI1 (ecotropic 
viral integration site 1).
237
 There is a PR domain at the N-terminal of MEL1 protein, 
repressor domain (RD) in the middle of the protein and two DNA binding domains which 
contain either 7 or 3-C2H2 type zinc figure repeats. PR domain of MEL1 protein is 52% 
identical to the N-terminal PR domain of the MDS1 protein and the RD contains a 
consensus binding sequence for the CtBP2.
237
 Later study found out there were actually 
three transcription start sites in MEL gene, one in exon 1 and two in exon2, which 
generated two protein products, 170kD MEL1 and 150kD MEL1S.
238
 MEL1S is the main 
isoform expressed in t (1; 3) (p36; q21)-positive AML cells and is translated from the 
internal initiation codon ATG579 in exon4.
238
 MEL1S protein lacks most of the PR 
domain compared with MEL1 protein.
238
 Aberrant expression of MEL1S gene due to 
chromosome translocation and vector insertional activation was associated with 
MDS/AML and T-cell leukemia.
223-226,238-240
 Prdm16 is mouse homolog of human 
PRDM16/MEL1 and its protein structure is shown in Figure 1-5. 
 
 
PRDM16 expression pattern and functions 
 
In mouse embryo Prdm16 mRNA was first detected on E9.5 predominately in the 
neuroepithelum lining  the telencephalic vesicle (TV), mesenchyme of the first branchial 
arch and dorsal aspect of somites and further expanded to the neuroepithelium of the 
hindbrain and in the optic stalk (OS), mesenchyme of the second and third branchial 
arches, limb bud (LB) and the facio-acoustic preganlion complex (FACP) on E10.5.
241
 
During E11.5 to E12.5 Prdm16 expression expanded to liver, heart, lung epithelium 
stomach, duodenum and brain, especially in neuroepithelium lining the third ventricle, 
Meckel’s cartilage (MC) and future nasal spetum (NS) in the orofacial region and dorsal 
root ganglia (DRG).
241
Prdm16 showed much broader expression pattern on E14.5, 
encompassing mutli tissues including brain, olfactory epithelium (OE), testis, pancreas, 
kidney adrenal gland (AG), lung, DRG, cartilage primordial of the ribs (CPR), limbs, 
retina and in the lens also.
241
 Widespread expression of Prdm16 in mouse embryo 
suggests role of Prdm16 in tissue/organ specification or growth.  
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Denis, R.W et al identified PRDM16 as a SMAD3 binding protein mouse in 
orofacial tissue during E12.5 to E14.5, but PRDM16/SMAD3 interaction did not 
significantly alter TGFβ signaling.242 Although the molecular mechanism of Prdm16 
during orofacial development is not clear, great progress has been made to understand the 
role of Prdm16 in BAT differentiation. There is evidence showing that PRDM16 
functions as a co-regulatory protein controlling molecular switch between white fat and 
brown fat identity (Figure 1-5).
185,201,202
 Prdm16 transcript is highly expressed in primary 
brown fat tissue and immortalized brown fat cell lines and overexpression of PRDM16 
was able to induce BAT phenotype from PPAR-γ expressing white fat precursors or 
fibroblasts.
213
 PRDM16-mediated identity switching between white and brown adipose 
tissue was achieved by binding partner switching. Mouse PRDM16 directly binds to 
CtBP-1 and CtBP-2 as co-repressors to transcriptionally repress WAT differentiation 
program through direct interaction with the promoter of white fat specific genes.
214
 When 
CtBP-1 and CtBP-2 are replaced by PGC-1α (PPAR-γ-coactivator-1α) and PGC-1β 
(PPAR-γ-coactivator-1β), transcription activity of PGC-1α and PGC-1β are increased and 
activate brown fat genes.
214
 However, switching cell identity between skeletal muscle and 
BAT mediated by PRDM16 in Myf5
+
 myoblasts is not involved in white adipogenesis, 
suggesting independent molecular mechanism of repression of skeletal muscle 
differentiation.
214
 Enforced expression of PRDM16/C-EBP-β complex in myf5+ 
myoblasts is sufficient to initiate BAT differentiation program by inducing the PPARγ 
and PGC-1α expression.243 Recent study showed euchromatic histone-lysine-
methyltransferase 1(EHMT1), the enzymatic component of PRDM16 transcriptional 
complex, determines BAT fate versus muscle cell lineage by stabilizing PRDM16 protein 
and controlling H3K9 methylation status of the muscle-specific gene promoters.
244
 
 
Besides PRDM16’s role in promoting BAT identity, there is also evidence 
showing that PRDM16 executes important function in developing telencephalon through 
repressive regulation of Hes1
189
 and functions as H3K9me1 methyltransferase to 
maintain the integrity of mammalian heterochromatin.
245
 In the next two paragraphs I 
will focus on the Prdm16’s role in normal and leukemic hematopoiesis. 
 
 
PRDM16’s role in normal hematopoiesis 
 
Prdm16 transcript is preferentially expressed in purified LT-HSC, ST-HSCs and 
MPPs.
215,216
 Enforced expression of Prdm16 on mouse adult CD150
+
CD48
-
Lin
-
 cells led 
to enhanced HSC reconstitution capacity and poorly differentiated myeloid cells in 
recipients’ bone marrow, which developed splenomegaly and myeloproliferation 20 
weeks post transplantation.
246
 Loss of Prdm16 depleted fetal liver and new born liver 
HSPCs, leaving remaining neonatal and adult HSCs with compromised long-term 
reconstitution capacity and Prdm16
-/-
 HSCs contain increased proportion of HSCs 
undergoing apoptosis/cell death and active cell division.
215,216
 Gene expression data from 
Prdm16
-/-
 HSCs suggested that Prdm16 regulates multiple pathways/regulators to 
maintain HSC function, including p53 related apoptotic pathway, cell cycle regulator 
Cdkn1a, transcription factors critical for HSC maintenance and Wnt signaling pathway 
components Wnt3a and Ryk206. Gathering all the data, it suggests Prdm16 is required 
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for fetal and adult HSC maintenance and overexpression of Prdm16 is able to enhance 
HSC activity in vivo. However, the fact that enforced expression of Prdm16 in HSCs led 
to undifferentiated HSCs in vitro and myeloproliferation in recipients unveiled Prdm16’s 
oncogenic potential, which may be related to the function of human PRDM16 in AML. 
The role of PRDM16/sPRDM16 in hematopoietic malignancies will be discussed in the 
following paragraphs. 
 
 
PRDM16’s role in leukemic hematopoiesis 
 
Most evidences of association between PRDM16 and hematopoietic malignancies 
come from the studies of human AML involved chromosome translocation. Since 
PRDM16/MEL1 was first isolated from t(1;3)(p36;q21)-positive MDS/AML patient 
leukemia cells,
237
 there are growing evidences showing sPRDM16/MEL1S, lacking most 
of PR domain, is the major isoform highly expressed in t(1;3)(p36;q21)-positive 
MDS/AML as fusion partner with RPN1
238,239
 and t(1;21)(p36;q22)-positive therapy-
related MDS/AML as fusion partner of RUNX1.
224,225,247
 The RUNX1-PRDM16 gene is 
highly homologous to MDS1/EVI1 gene,
237
 suggesting RUNX1-PRDM16 may share 
similar mechanism in leukemic progress. sPRDM16 is also overexpressed in adult T cell 
leukemia with normal karyotype leukemias due to hypomethylation of regions 
surrounding sPRDM16 transcription start site
223
. Instead, the full-length PRDM16 is 
silenced by DNA hypermethylation of its promoter.
223
 This provided alternative 
epigenetic mechanism of aberrant and predominant expression of sPRDM16 in T-cell 
leukemia. Overexpression of sPRDM16 but not full length of PRDM16 led to myeloid 
leukemia in p53 null mice, indicating the cooperative effects of sPRDM16 and loss of 
p53 in murine AML pathogenesis.
248
 Du. Y et al showed Prdm16 is one of the frequent 
MSCV integration spots resulting in aberrant expression of sPRDM16, but not PRDM16, 
which led to immortalization of murine bone marrow progenitors.
227
 Upregulation of 
sPrdm16 due to insertional activation by γ-retroviral SIN vector is sufficient to induce 
leukemia in mice.
240
 In summary, sPRDM16 plays role in leukemogenesis through 
chromosome translocation, promoter hypomethylation or vector insertional mutagenesis 
although the molecular mechanism is still unclear. 
 
 
Thesis 
 
Unlike oncogenic HOX genes like HOXA9 and HOXA10, HOXB4 overexpression 
can mediate murine HSC expansion in vivo without leading to hematopoietic 
malignancies. Though many studies were carried out to identify HOXB4 target genes and 
these studies offered some insights regarding the mechanism of HOXB4-mediated HSPC 
expansion in vitro, survival and specification of ES cells, there are still questions listed 
below remaining unknown regarding HOXB4-mediated HSC expansion. 
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Questions 
 
1. What are HOXB4’s transcriptional target genes in transplanted mice? 
2. What are the pathways HOXB4 functions through to achieve robust HSC 
expansion in vivo? 
3. What is the mechanism by which HOXB4 avoids leukemogenesis in 
transplanted mice?  
 
 
Hypothesis 
 
By reviewing previous literatures about HOXB4-mediated HSC expansion; 
Prdm16’s role in HSC maintenance; association of sPrdm16activation with leukemia in 
HOXB4 transplanted animals, we generated our hypothesis to answer the questions 
above. The hypothesis is: 
 
HOXB4 downregulates Prdm16 to avoid leukemia in transplanted mice, co-
overexpression of sPrdm16 and HOXB4 will lead to hematopoietic cell transformation. 
 
 
Rationales 
 
 The Rationales of the hypothesis are listed as follows: 
 
1. Overexpression of HOXB4 leads to murine HSC expansion without causing 
hematopoietic malignancies. 
2. Activation of sPrdm16 due to vector integration promotes leukemogenesis in 
HOXB4-overexpressing cells in large animals. 
3. Growth of leukemia cells from HOXB4-transplanted animal is dependent on 
the sPrdm16 expression. 
4. PRDM16 expression is upregulated in HOXA9-asscoated leukemias. 
5. Aberrant expression of sPRDM16 due to chromosome translocation or 
promoter hypomethylation is frequently detected in MDS/AML or adult T cell 
leukemias. 
6. Overexpression of sPRDM16 led to myeloid leukemia in p53-null mice. 
7. Enforced expression of sPrdm16 blocks G-CSF induced granulocytic 
differentiation in L-G3 cells. 
 
 
Specific aims 
 
1. Identify target genes and pathways regulated by HOXB4 in LSK cells from 
recipient mice at 6, 12 and 20 weeks post transplantation. 
2. Find out and validate the mechanism by which HOXB4 avoid leukemia in 
vivo. 
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Approach 
 
 
Specific aim 1 
 
To identify HOXB4 transcriptional target genes and its regulated pathways we 
will perform gene expression profiling on HOXB4-overexpressing LSK cells from 
transplanted mice at 6, 12 and 20 weeks following transplantation. A two-factor ANOVA 
analysis will be applied to identify differentially expressed target genes and Gene Set 
enrichment assay (GSEA) and MetaCore pathway analysis will be used to identify 
pathways regulated by HOXB4. Quantitative real-time PCR will be performed to validate 
differential gene changes in CD34
-/low 
LSK cells, which are highly enriched with HSCs. 
 
Gene expression array provided by Hartwell Center for Bioinformatics and 
Biotechnology of St. Jude Children’s Research Hospital requires at least 100ng mRNA 
with concentration of at least 33ng/ul. The major challenge of perform gene expression 
array on rare population is inadequate mount of RNA. In this study we plan to apply 
expression on LSK cells, which is about 0.3% of total bone marrow cells. Our HOXB4 
retroviral vector can achieve about 30% transduction and around 90% for GFP vectors. 
Trial experiments showed that we are able to extract enough RNA for microarray from 3-
5 mice. 
 
 
Specific aim 2 
 
To identify the mechanism by which HOXB4 avoids leukemia in transplanted 
animals we will screen the differentially regulated transcriptional target genes generated 
from microarray discussed above. They can be genes (1) critical for HSC differentiation 
or apoptosis, (2) tumor suppressors upregulated by HOXB4, (3) oncogenes 
downregulated by HOXB4. To validate the potential factor involved in avoiding 
leukemia, target gene will be overexpressed or knockdown using lentiviral vector under 
the context of HOXB4 overexpressing to screen leukemia in transplanted mice. 
 
We have generated and well characterized lentiviral overexpression and 
knockdown vectors that can be used in this study. We also developed efficient HSC or 
HPC transduction protocol which allows us to generate enough double positive cells for 
transplantation. Flow cytometry core, Pathology department and Animal Resource Center 
of St. Jude Children’s Research Hospital are able to offer us professional assistance for 
cell sorting and analysis, animal necropsy, animal care. 
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CHAPTER 2.    IDENTIFICATION OF HOXB4 TRANSCRIPTIONAL TARGET 
GENES IN PRIMITIVE HEMATOPOIETIC CELLS IN VIVO 
 
 
Introduction 
 
As mentioned earlier overexpression of HOXB4 leads to marked murine HSC 
expansion in vivo without causing hematopoietic malignancies. Little is known about the 
mechanism how HOXB4 expands HSCs and at meanwhile prevents leukemogenesis. To 
understand the regulatory role of HOXB4 in HSCs expansion, many studies were carried 
out to screen HOXB4’s direct or indirect target genes and pathways important for HSCs 
maintenance, proliferation and differentiation. Microarray data from either enriched adult 
HSCs or embryonic derivatives expressing HOXB4 demonstrated that HOXB4 
transcriptionally activates c-Myc
249
 and down-regulates genes involved in TNF-α and 
FGF signaling in bone marrow cells,
250
 thus proving beneficial for HSCs self-renewal. 
Gp49a, Laptm4b and Hemgn were identified as HOXB4 downstream targets and 
suggested to be potentially important for HSCs’ stemness or expansion of myeloid 
progenitors in vitro.
251,252
 These earlier studies suggested that HOXB4 controls HSC or 
myeloid progenitors through multiple mechanisms such as apoptosis and symmetric 
division/proliferation. However, it is noticed that none of the previous studies focused on 
HOXB4 targets in primary primitive hematopoietic populations in vivo. To overcome the 
limits of previous screenings we decide to screen HOXB4’s target genes in LSK cells 
during different phases of the reconstitution in vivo.  
 
To screen HOXB4 target genes and pathways in LSK cells from transplanted 
mice, we plan to transplant HOXB4 overexpressing bone marrow cells to lethally 
irradiated mice and extract RNA of LSK cells from recipients at 6, 12 and 20 weeks 
following transplantation for expression array assay. Compared with previous studies 
done on manipulated cells lines or by using in vitro system, target genes identified from 
transplant mouse model will be more informative about how HOXB4 expands HSCs in 
vivo. 
 
 
Materials and Methods 
 
 
Vector cloning 
 
The retroviral vectors MSCV-ires-GFP and MSCV-HOXB4-ires-YFP have been 
described previously.
251
 
 
 
Retroviral vector preparation 
 
Retroviral vectors of MSCV-ires-GFP or MSCV-HOXB4-ires-YFP were 
prepared as described before.
251
 The helper-free recombinant retroviral vector supernatant 
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was freshly collected from the GPE+86 producer cells and filtered through 0.45 µm pore 
filter for transduction. 
 
 
Bone marrow cells isolation, culture, transduction and transplantation 
 
All animal experiments were carried out according to protocols approved by the 
St. Jude Institutional Animal Care and Use committee. To harvest primitive bone marrow 
cells, 5-Fluorouracil (5-FU) (150 mg/kg) was injected intravenously into 6 to 8-week-old 
female c57BL/6J mice. 5 days after injection bone marrow cells were flushed with 21-
gauge needles from both femurs and tibias in to ice cold DPBS containing 2% FBS. 5-FU 
treated were cultured in DMEM supplemented with 15% fetal bovine serum (FBS), 50 
units/ml penicillin, 50 units/ml streptomycin, 2mM L-glutamine, 20 ng/ml recombinant 
mouse IL-3, 50 ng/ml human IL-6, and 50 ng/ml mouse SCF (R&D Systems, 
Minneapolis, MN). 
 
To transduce bone marrow cells with gamma retroviral vector, 5-FU treated BM 
cells were prestimulated with cytokine mixture mentioned in the previous paragraph for 
48 hours to induce quiescent hematopoietic stem cells to enter cell cycle. After two days’ 
prestimulation 1x10
6 
bone marrow cells were transduced with fresh unconcentrated 
supernatant from GPE+86-derived producer cells containing MSCV-HOXB4-ires-YFP or 
MSCV-ires-GFP retroviral vectors in 6-well plates preloaded with 25ug/ml retronectin 
(Takara). After two to four daily exposures to vector, 1 to 2 million transduced cells were 
injected into the lateral tail vain of lethally irradiated (1100cGy) female C57Bl/6L mice. 
Transplanted mice were under Baytril water administration for 3 weeks post 
transplantation and Baytril water was changed weekly. 
 
 
Cell separation 
 
BM cells were stained with Sca-1-PE, c-Kit-APC and a PE-Cy7 conjugated 
lineage antibody mixture (CD4, CD8, Gr1, Ter119 and NK1.1) (BD Bioscience). GFP
+
 
or YFP
+
 LSK cells were isolated by flow cytometry. 
 
 
Colony forming assay 
 
Total 500 vector positive LSK cells from HOXB4 or GFP transplanted mice at 12 
and 20 weeks post transplantation were into 1ml MethoCult GF M3434 methylcellulose 
medium (StemCell Technologies, Vancouver, BC, Canada) containing various cytokines 
supporting growth of clonogenic myeloid progenitor cells. After 7 days, primary (1°) 
colonies were scored, collected, resuspended, and re-plated at 1x10
4
 cells/ml density into 
the M3434 methylcellulose medium for 14 days culture. The generated secondary (2°) 
colonies were scored to quantitate the expansion of myeloid progenitors. 
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Microarray expression analyses and real-time RT-PCR 
 
Total RNA from sorted LSK cells was extracted using RNAqueous®-Micro kit 
(Life Technologies). Approximately 20ng total RNA was processed using NuGEN WTA 
pico v2 and Encore Biotin labeling modules and 6ug of biotin-labeled cDNA was 
hybridized overnight to HT_MG-430_PM microarray chips (Affymetrix). Hybridized 
arrays were scanned using the Gene Titan system and signals were summarized using the 
RMA method (Partek Genomics Suite v6.5). Differentially expressed transcripts between 
GFP+ LSK and HOXB4+ LSK cells were identified from triplicate, independently 
derived from pools of cells at various time points using a two-factor ANOVA model. The 
Benjamini-Hochberg method
253
 was used to estimate the False Discovery Rate (FDR). 
Pathways activated or repressed by HOXB4 expression were identified by GSEA
254
 using 
curated pathways obtained from the MolSigDB (Broad Institute) and Ingenuity Pathways 
(Ingenuity, Inc.). MetaCore
TM
 software (GeneGo, Philadelphia, PA) was also used to 
identify significant biological pathways defined by specific differentially expressed 
genes. 
 
To validate gene expression changes detected in microarray study, GFP
+
 or 
HOXB4-YFP
+
 CD34
-/low
 LSK cells were sorted from transplanted mice 20 weeks post 
transplantation. Total RNA sorted cells were reverse transcribed using SuperScript VILO 
cDNA Synthesis Kit (Life Technologies). Resulting cDNAs were quantitated by qRT-
PCR assay using Power SYBR® Green PCR Master Mix (Life Technologies). The 
relative expression levels for specific transcripts were calculated using the 2
ΔΔCT
 method 
normalized to the internal control gene Gapdh.  
 
 
Results 
 
 
HOXB4
+
LSK cells demonstrated enhanced hematopoietic progenitor cell self-
renewal in vitro 
 
To demonstrate HOXB4-enhanced hematopoietic progenitors’ clone forming 
capacity in vitro, 500 HOXB4-YFP
+ 
LSK cells or control GFP
+
 LSK cells from 12 and 20 
weeks transplant mice were plated into MethoCult GF M3434 to score the secondary 
colony numbers. HOXB-LSK from 12 week transplanted mice generated 169 secondary 
colonies, about 9 times more than GFP control LSK cells from the same time point 
(P<0.01) (Figure 2-1). HOXB4-LSK cells from 20 weeks transplant mice generated 395 
secondary colonies, 15 times more than GFP control LSK cells at same time point 
(P<0.01) (Figure 2-1). Increased secondary colony number generated from HOXB4-LSK 
at both 12 and 20 weeks post transplantation indicated enhanced hematopoietic 
progenitor cell self-renewal in vitro. It also suggested RNA samples collected from the 
same batch of cells for microarray were validated. 
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Figure 2-1. Secondary colony numbers generated from 1x10
4
 GFP-LSK cells or 
HOXB4-LSK cells at 12 or 20 weeks post transplantation. 
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Global gene expression changes in HOXB4-transduced LSK cells at various time 
points after transplant 
 
To identify both direct and indirect transcriptional target genes of HOXB4 in 
HSCs, we generated a MSCV-HOXB4-ires-YFP vector and a control GFP vector based 
on the MSCV γ-retroviral vector (Figure 2-2A). Groups of mice were transplanted with 
transduced bone marrow cells and then euthanized at 6, 12, and 20 weeks after transplant 
for gene expression analysis (Figure 2-2B). Gene expression profiling was performed on 
HOXB4-YFP or control GFP-expressing bone marrow LSK cells isolated by cell sorting 
(Figure 2-2C). At most time points, sufficient amounts of RNA were isolated for 
microarray analysis (Table 2-1). For all time points, three independent transplant 
experiments and cell isolation procedures were performed to establish reproducibility. 
 
Principal component analysis (PCA) using all expression profiles measured by the 
microarray revealed significant clustering within experimental groups (Figure 2-3A). 
The GFP samples and the HOXB4 samples separated across the first principal component 
indicating the most significant source of expression variation was associated with 
presence or absence of HOXB4 expression. Within the GFP treatment arm, the 12 and 20 
week samples grouped closely together. Within the HOXB4 treatment arm, the 12 and 20 
week samples also grouped together and were statistically distinct from the GFP-control 
groups (Figure 2-3A). The 6 week samples from the HOXB4 treatment arm were 
separated from the 12 and 20 week HOXB4 samples, demonstrating distinct 
transcriptional profiles exist at these two time points. A heat map representation of all 
expression profiles shows reproducible gene expression changes in HOXB4-transduced 
LSK cells that evolve between 6 and 20 weeks after transplant (Figure 2-3B). These gene 
expression patterns were consistent in triplicate samples from both groups and were 
highly reproducible within each experimental arm. 
 
 
Identification of specific changes in gene expression in HOXB4-transduced LSK 
cells 
 
To identify either direct or indirect HOXB4 target genes, we applied a two-factor 
ANOVA model to identify probe sets with >0.5 log difference and with a FDR of <0.05 
in the HOXB4 versus the GFP groups at given time points. In the HOXB4-LSK cells, a 
total 520 and 1712 probe sets were identified with significant differential expression at 12 
weeks and 20 weeks when compared with control GFP-LSK cells (Figure 2-4A, B). 
When 6 week HOXB4 samples were compared with the 12 and 20 week HOXB4 
samples, 379 and 622 probe sets showed >0.5 log deference and FDR<0.05 respectively 
(Figure 2-4C, D). However, no significant differential gene expression was noted 
between 12 and 20 week in HOXB4
+
 LSK cells, demonstrating that the major 
transcriptional events in HOXB4 transduced cells occur by 12 weeks after 
transplantation. Heat maps of the top 35 over and under-expressed genes at 20 weeks 
show reproducible and significant differences in HOXB4samples versus GFP samples 
(Figure 2-4E).  
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Figure 2-2. Experimental design of HOXB4 target gene analysis in transplanted 
murine HSCs.  
(A) Schematic diagram of HOXB4 retroviral and GFP control vectors used to transduce 
5-FU treated bone marrow cells. (B) Time line of transduction and mouse transplantation 
assay. (C) Flow cytometry sorting strategy for transduced LSKs. Bone marrow cells 
isolated from recipients were first gated for lineage negative cells, then for cKit
+
, Sca-1
+
 
marker status, and then for vector expression based on GFP or YFP expression. Sorted 
GFP/YFP
+
 LSK cells were used for subsequent gene expression analyses. 
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Table 2-1. Summary of RNA samples submitted for microarray from GFP or 
HOXB4 group at 6 weeks, 12 weeks and 20 weeks. 
 
Group Time Point Recipient 
No. 
LSK No. Amount of RNA 
(ng) 
HOXB4 6 weeks 2 12653 38.045* 
HOXB4 6 weeks 2 33599 51.2* 
HOXB4 6 weeks 4 178567 65.15* 
GFP 12 weeks 2 103797 24.365* 
GFP 12 weeks 2 132398 43.09* 
GFP 12 weeks 3 32196 37.505* 
HOXB4 12 weeks 2 232034 153.7* 
HOXB4 12 weeks 2 145500 158.35* 
HOXB4 12 weeks 3 280349 209.8* 
GFP 20 weeks 2 25532 33.782* 
GFP 20 weeks 2 261449 221.4 
GFP 20 weeks 2 11181 93.76* 
HOXB4 20 weeks 2 139257 172.54 
HOXB4 20 weeks 2 166132 252.2 
HOXB4 20 weeks 2 200269 411 
* indicates the samples from which RNA was concentrated using sodium acetate 
precipitation.  
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Figure 2-3. PCA and heat map representation of HOXB4-induced expression 
profiles in bone marrow LSK cells. 
(A) PCA using all probe sets where each symbol represents an separate experiment as 
indicated by the legend, with red symbols denoting HOXB4 samples and blue symbols 
the GFP controls. The GFP
+
 LSK cells and HOXB4
+
 LSK cells segregate into 
statistically separate groups across PC1 axis. HOXB4-LSK cells harvested at 6 weeks are 
distinct from 12wk and 20wk HOXB4-LSKs across the PC2 axis. (B) Heat map of gene 
expression alterations seen across all probe sets, with triplicate samples per experimental 
arm and time points as indicated by the labels. Red indicates over-expressed probe sets 
relative to GFP controls while green indicates under-expressed probe sets. 
  
 38 
 
 
Figure 2-4. Identification and validation of HOXB4 target genes. 
Bland-Altman plots showing comparative gene expression between (A) 12wk HOXB4-
LSKs and 12wk GFP-LSKs (B) 20wk HOXB4-LSKs and 20wk GFP-LSKs (C) 12wk 
HOXB4-LSKs and 6wk HOXB-LSKs and (D) 20wk HOXB4-LSKs and 6wk HOXB4-
LSKs. The y-axis indicates the magnitude of change and the x-axis the average of the 
signal. The red dots represent differentially expressed probe sets with a >0.5 log 
differential expression and false discovery rate (FDR) <0.05. (E) Heat map of the top 
upregulated and downregulated genes from 20wk HOXB4-LSKs compared with 20wk 
GFP-LSKs. Red represents upregulated genes and blue boxes represent downregulated 
genes. (F) Quantitative RT-PCR measurement of differential gene expression for 13 
HOXB4-regulated genes in CD34
-/low 
LSK cells at 20 weeks post transplantation. The 
fold change is indicated for HOXB4 cells relative to GFP cells. (G) Quantitative RT-PCR 
for expression of Prdm16 mRNA in LSK cells harvested from transplanted mice at 6 
weeks and 39 weeks post transplantation. 
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CD34
-/low
 LSK cells were isolated 20 weeks after transplant. Reverse qRT-PCR 
was used to measure mRNA levels for a subset of differentially expressed transcripts 
potentially involved in HSC regulation (Figure 2-4F). GATA2 is a zinc-finger 
transcription factor that is required for adult HSC development
44
 and was increased 4 fold 
in HOXB4 transduced HSCs. Hemgn was identified as a HOXB4 direct target in HOXB4 
transduced hematopoietic progenitor cells in our previous study
251
 and was increased 3.0 
fold relative to that seen in GFP control cells (Figure 2-4F). TGF-beta signaling is a 
negative regulator of HSC proliferation and utilizes SMAD proteins as downstream 
effector molecules
84
. Expression of Smad1 and Smad7 were 3.6 and 2.4 fold up-regulated 
by qRT-PCR in HOXB4-transduced CD34
-/low
 LSK cells (Figure 2-4F).  
 
A 3-18 fold down-regulation of Prdm16 was noted in all 4 microarray probes 
from the HOXB4 samples at 20 weeks. PRDM16 is a SET domain-containing protein 
associated with epigenetic remodeling and is required for brown fat 
determination
197,213,214
 and adult murine HSC and neural stem cell maintenance.
215
 We 
noted a 58.1 fold down-regulation of Prdm16 mRNA by qRT-PCR in HOXB4 samples 
compared with GFP controls at 20 weeks (Figure 2-4F). A time course of Prdm16 
mRNA expression showed large decreases in Prdm16 transcripts in HOXB4-LSK cells at 
6 weeks and 39 weeks respectively (Figure 2-4G), demonstrating that downregulation of 
Prdm16 occurs at both early and late times after transplant. 
 
 
HOXB4 overexpression results in gene expression changes associated with HSC self-
renewal and lymphoid-myeloid differentiation 
 
To further define the regulatory pathways underlying HOXB4-dependent HSC 
expansion, we performed GSEA with curated gene sets associated with signaling, 
metabolic, and differentiation pathways. HOXB4 expression at 20 weeks after transplant  
produced significant activation of genes associated with HSC function (Figure 2-5A).
255
 
This trend was also seen at 12 weeks in the HOXB4 arm but did not reach statistical 
significance. Activation of genes associated with long term hematopoietic stem cell 
potential was also observed in HOXB4-transduced LSK cells at 20 weeks but not at 12 
weeks (FDR < 0.05).  The highest over-expressed genes in the HSC pathways included 
Jun, Evt1, Smad7, Angpt1, Laptm4b, Hoxa5, and Hoxa10 (Figure 2-5B). 
 
The top canonical pathways activated and repressed in HOXB4-LSK cells at 20 
weeks (Tables 2-2, 2-3) include multiple signaling, differentiation, and metabolic 
pathways. In particular, a distinct B cell differentiation pathway (Ingenuity, Inc.) was 
activated in HOXB4+ LSK cells at both 12 and 20 weeks (Figure 2-5C). Rag2, Rag1, 
Pax5, Bcl11a and other genes important for B cell differentiation were activated in 
HOXB4
+
 LSK cells (Figure 2-6A). Pathway analysis of differentially expressed 
transcripts using MetaCoreTM software identified several myeloid differentiation 
pathways as being activated by HOXB4 in LSK cells (Figure 2-5D). These included 
Development_Transcription regulation of granulocyte development and Development_G-
CSF-induced myeloid differentiation as the top two most significantly activated pathways 
in 12 and 20 weeks HOXB4-LSK cell samples (Figure 2-5D). Overexpressed genes in  
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Figure 2-5. GSEA and MetaCore pathway analysis of HOXB4 responsive genes. 
(A) GSEA analyses for HOXB4 regulated genes identified for hematopoietic stem cell 
pathways. For each GSEA, the nominal p-value and FDR q-value are shown below each 
pathway graph. Statistical significance was validated for both pathways in 20 week 
samples. (B) Heat map gene expression changes in individual gene probe sets within the 
Hematopoiesis Stem Cell pathway and Hematopoiesis Stem Cell Long Term pathway in 
LSKs analyzed at 12 and 20wks after transplant. Red boxes represent upregulated genes 
and blue boxes represent downregulated genes. (C) GSEA analysis B cell differentiation 
pathway genes altered by HOXB4 in 12 and 20 week LSK samples. Statistical parameters 
are listed below each analysis. (D) Pathway analysis of differentially expressed probe sets 
using MetaCore
TM
 program analysis showing the top 10 pathways regulated by HOXB4 
at 12 (yellow) and 20 weeks (blue) post transplantation. The x-axis scale shows the -
10log (p-value) of each pathway.  
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Table 2-2. Pathways activated in HOXB4-LSKs at 20 weeks. 
 
Name Size ES NES NOM p-val FDR q-val 
KEGG_PRIMARY_IMMUNODEFICIENCY 35 0.67463 2.02402 0 0.013965 
REACTOME_THROMBIN_SIGNALING_THR
OUGH_RPOTINASE_ACTIVATED_RECEPT
ORS 
27 0.63399 1.84257 0.00168 0.16151 
IP_B_CELL_DIFFERENTIATION 20 0.690918 1.83225 0 0.12314 
BIOCARTA_RHO_PATHWAY 32 0.605903 1.82660 0.00543 0.102322 
KEGG_VASCULAR_SMOOTH_MUSCLE_CO
NTRACTION 
108 0.479403 1.82660 0 0.166082 
BIOCARTA_BCR_PATHWAY 33 0.59260 1.77393 0.00347 0.151108 
BIOCARTA_PGC1A_PATHWAY 22 0.64729 1.75932 0.00355 0.156613 
REACTOM_INHIBITION_OF_INSULINE_SE
CREATION_BY_ANDRENALINE_NORADR
ENALINE 
30 0.59687 1.74797 0.001694 0.159273 
BIOCARTA_CTCF_PATHWAY 23 0.62738 1.747828 0.005300 0.141576 
REACTOME_SIGNAL_AMPLIFICATION 31 0.582232 1.74742 0.003442 0.127858 
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Table 2-3. Pathways activated in GFP-LSKs at 20 weeks. 
 
Name Size ES NES NOM p-val FDR q-val 
KEGG_LYSOSOME 116 -0.59061 -2.2849 0 0.00143257 
REACTOME_P53_INDEPENDENT_DNA_DAM
AGE_RESPONSE 
42 -0.68597 -2.2615 0 7.16E-04 
REACTOME_CDT1_ASSOCIATION_WITH_TH
E_CDC6_ORC_ORIGIN_COMPLEX 
45 -0.67419 -2.2377 0 4.78E-04 
KEGG_PROTEASOME 44 -0.67331 -2.2255 0 7.14E-04 
REACTOME_ELECTRON_TRANSPORT_CHAI
N 
62 -0.62747 -2.2045 0 5.71E-04 
REACTOME_METABOLISM_OF_CARBOHYD
RATES 
110 -0.5745 -2.1961 0 4.76E-04 
REACTOME_STABILIZATION_OF_P53 45 -0.6662 -2.1781 0.002341 5.99E-04 
REACTOME_SCF_SKP2_MEDIATED_DEGRA
DATION_OF_P27_P21 
50 -0.6433 -2.1659 0 8.47E-04 
REACTOME_CYCLIN_E_ASSOCIATED_EVEN
TS_DURING_G1_S_TRANSITION_ 
56 -0.62507 -2.1562 0 7.53E-04 
KEGG_PENTOSE_PHOSPHATE_PATHWAY 26 -0.7229 -2.1551 0 6.78E-04 
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Figure 2-6. Activation of B cell differentiation and Granulocyte development/ G-
CSF-induced myeloid differentiation in 12wk and 20wk HOXB4-LSKs. 
(A) Heat map of genes of B CELL DIFFERENTIATION pathway activated in 12wk and 
20wk HOXB4-LKSs. (B) Demonstration of activated components in granulocyte 
development and G-CSF-induced myeloid differentiation signaling pathways in 12wk 
and 20wk HOXB4-LKSs. 
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these pathways included genes encoding the G-CSF receptor as well as C/EBPalpha, 
Myeloblastin, Lactoferrin, Leukocyte elastase, and Gp91-phox (Figure 2-6B). 
Altogether, these results suggest HOXB4’s function may also include lineage-specific 
priming events in committed cells that are present within the heterogeneous LSK 
population. 
 
 
Discussion 
 
 
Advantage of gene profiling study in LSK cells from HOXB4 transplanted mice 
 
Enforced expression of HOXB4 causes a controlled expansion of murine HSCs in 
vivo until HSC numbers approximate that seen in untransplanted mice. The genes that 
control this expansion have not been previously identified and are likely relevant for the 
physiologic regulation of HSC pool size or leukemogenesis in transplanted mice. Prior 
gene expression profiling studies have identified various HOXB4 target genes in different 
systems
250-252,256,257
 yet these studies show little overlap in identified target genes. None 
of these previous studies included analyses of primary adult HSCs derived directly from 
HOXB4 transplanted animals. Even less is known about how HOXB4 transcriptional 
events are dynamically regulated at various times during HSC reconstitution. This study 
addresses these questions by defining the HOXB4 transcriptional program directly in 
LSK cells (HSC-enriched population) derived from the bone marrow of transplanted 
mice at multiple time points. Although majority of LSKs are composed of restricted 
progenitors, expression changes of genes critical for HSCs function were validated on 
CD34
-/low 
LSK cells, which are high enriched with HSCs. Quantitative real-time PCR on 
CD34
-/low 
LSK cells confirmed the gene expression changes of key HSC regulators shown 
in gene expression array. 
 
 
Mechanism of well-maintained HSC pool size by HOXB4  
 
Our gene expression array data (PCA and heat map) showed that the HOXB4 
gene expression pattern in transplanted LSK cells was fully established by 12 weeks after 
transplant. This is consistent with the known kinetics of HOXB4-induced HSC expansion 
in which HSC numbers in the bone marrow were normal and stable by 12 weeks after 
transplant, but not at 8 weeks.
181,182
 The fact that the kinetics of the gene expression 
changes correlate with the plateauing of HSC numbers further establish that HOXB4 
mediated HSC effects are transcriptionally mediated. GSEA showed that both short and 
long term HSC expression profiles were activated by HOXB4 expression and involved 
regulation of a number of genes known to be important for HSC function and self-
renewal.  
 
When taking close look at the genes critical for HSC proliferation, quiescence and 
apoptosis, Smads, Gata2, Bcl3 and Prdm16 would be executors which regulate HSC pool 
size in HOXB4 transplanted mice. SMAD-1 (R-Smad) and SMAD-7 (I-Smad) are 
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mediators of TGF-β/BMP signaling pathway, which execute ligand-specific regulation of 
HSC proliferation, differentiation and apoptosis and in some cases bone marrow niche is 
required. Smad1 and Smad7 were upregulated in HOXB4-LSK/CD34
-/low
 LSK cells. 
Smad7 increases HSC self-renewal in vivo while effect of Smad1 on adult HSC is not 
clear, although Smad1 was required for embryonic hematopoiesis. Considering Smad1 is 
activated by TGF-β1 receptor which has negative effect on HSC self-renewal and 
differentiation and promotes HSC apoptosis, we assume that activation of Smad1 in 
HOXB4 transplanted mice had negative regulation of HSC pool size. The ultimate 
outcome is decided by the balanced effect of Smad1 and Smad7. GATA2, a transcription 
factor inhibiting hematopoietic precursor from differentiation and maintaining HSC/HPC 
at quiescent state,
45,46
 was upregulated by HOXB4 in LSK cells. It suggests GATA2’s 
role in maintaining HSC pool size. Another mechanism for HOXB4 to regulate HSC pool 
size is downregulation of Bcl3. BCL3 is a potential anti-apoptotic effector in HSCs and 
repression of Bcl3 results in increased apoptosis in HSCs, thus prevent HSC ‘runaway’ 
expansion. PRDM16 is another positive regulator of HSC which was marked 
downregulated by HOXB4. Prdm16 null mice are embryonic lethal because of loss of 
fetal liver HSCs due to enhanced apoptosis.
215,216
 Repression of Prdm16 expression can 
introduce apoptosis in HOXB4-LSKs, thus maintain HSC pool at physiological level. 
(Figure 2-7) 
 
In addition to these HSC signatures, network analyses revealed gene sets 
enrichment associated with B-cell and myeloid differentiation programs. Activation of 
these differentiation programs could reflect expression of lineage-associated genes that 
result from asymmetric HSC divisions producing committed progenitor cells. This is 
consistent with the widely held viewpoint that HSC pool size is regulated by establishing 
equilibrium between commitment/differentiation versus HSC self-renewal fates. The 
LSK cell pool contains seven functionally distinct subpopulations of HSCs and MPPs 
with myeloid-biased or lymphoid-biased or myeloid-lymphoid balanced reconstitution 
capacity in transplanted mice.
258
 Our data suggest that HOXB4 overexpression can  
induce both symmetric and asymmetric HSC replication in a balanced manner that leads 
to a stable HSC pool size by 12 weeks. 
 
To validate the hypothesis of the regulation of HSC pool size in HOXB4 
transplanted mice discussed above, limiting dilution assay to assess the HSC frequency 
should be performed. 
 
 
Mechanism how HOXB4 prevents leukemia in transplanted mice 
 
Overexpression of HOXA9 or HOXA10 can lead to myeloid leukemia because of 
increased HSC/HPC pool size and blocked downstream differentiation, during which 
collaboration of MEIS1 is required.
138-140
 It is known that HOXB4, unlike oncogenic 
gene HOXA9 and HOXA10, doesn’t cause hematopoietic malignancies in transplanted 
mice. Differentiation permission of proliferating HSCs is the key to prevent leukemia. 
GSEA and MetaCore pathway analysis indicate HOXB4 activates B cell and myeloid 
lineage differentiation, thus preventing accumulation of undifferentiated HSCs in bone   
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Figure 2-7. Regulation of HSC pool size in HOXB4 transplanted mice. 
Genes known important for HSC function, Smad1, Smad7, Gata2, Bcl3 and Prdm16, 
were regulated to maintain HSC pool size at physiological level. Maintenance of HSC 
pool size was achieved through regulation of HSC self-renewal, differentiation and 
apoptosis.  
 
Modified with permission. Larsson J, Karlsson S. The role of Smad signaling in 
hematopoiesis. Oncogene. 2005;24(37):5676-5692.
12
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marrow niche which could potentially lead to leukemia. However the molecular 
mechanism of the differentiation permission in HOXB4 expressing HSCs is not clear. 
PRDM16 as mentioned before is required for HSC maintenance 
duringembryogenesis
215,216
 and its aberrant expression is frequently detected in 
MDS/AML or T-ALL patients.
223-225,237-239,247,259,260
 Downregulation of Prdm16 by 
HOXB4 can serve a mechanism to prevent leukemia in transplanted mice. Due to 
chromosome translocation or vector insertional activation, short form of PRDM16 
(sPRDM16) lacking most of the PR domain is the major isoform expressed in leukemia 
patients. Overexpression of sPRDM16 but not full length of PRDM16 led to myeloid 
leukemia in p53 null mice.
248
 To prove the hypothesis that repression of Prdm16 is the 
mechanism to prevent leukemogenesis in HOXB4 transplanted mice, we plan to screen 
leukemia in transplanted mice receiving HOXB4 and sPRDM16 co-expressing cells in 
mice. We expect to detect myeloid leukemia in transplanted mice. It may require long 
latency or we will not detect any leukemia, which suggests additional genetic lesions are 
required to initiate leukemic transformation.  
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CHAPTER 3.    DOWNREGULATION OF PRDM16 PREVENTS LEUKEMIA IN 
HOXB4 TRANSPLANTED MICE 
 
 
Introduction 
 
Enforced expression of HOXB4 leads to increased HSC self-renewal without 
causing hematopoietic malignancies in transplanted mice
141,181
. Benign HSC expansion in 
vivo makes HOXB4 a perfect tool to expand HSCs for blood diseases. To identify the 
mechanism how HOXB4 prevents leukemogenesis, we investigated the expression 
profiling of HOXB4 expressing LSKs from transplanted, which suggested activated 
lineage priming and downregulation of AML-associated gene Prdm16 would be the 
reason. We focused on the study of sPrdm16 because of the association of sPrdm16 with 
human MDS/AML and T-TALL.
239,247,260
 Humphries group also reported the vector 
insertional activation of sPrdm16 which plays role in the myeloid leukemia developed in 
large animals transplanted with HOXB4 transduced CD34
+
 cells.
187
 At meanwhile 
Forget’s group screened 52 HOXB4 transplanted mice and 2 mice developed AML at 4 
and 9.5 months, respectively, following transplantation. Both leukemias were passaged 
by serial transplantation of leukemic bone marrow or spleen cells into WT recipient mice. 
Leukemia 1(L1) showed expression of Mac-1 and Gr-1 myeloid markers as well as 
CD16/32 and Sca1 (Figure 3-1A) and the second leukemia case (L2) demonstrated 
expression of myeloid (Gr-1, Mac-1), erythroid (Ter119), and B lymphoid (B220) 
markers (Figure 3-1B). Interestingly, identification of vector insertion sites revealed an 
intragenic integration in intron 1 of the Prdm16 gene and another integration event 
approximately 50kb upstream of Notch1 gene (Figure 3-2A). Increased levels of 
sPrdm16 and Notch 1 mRNA were confirmed in L2 leukemia cells (Figure 3-2B). 
Activation of sPrdm16 in large animals and mice suggested sPrdm16’s role in initiation 
or maintenance of leukemia in HOXB4 transplanted animals. However, we do not 
exclude other molecular changes which also can contribute to the leukemic 
transformation, because other pro-oncogenes were also activated by vector integration 
together with sPrdm16. In the following studies we decided to focus on sPrdm16 to 
initiate the further exploration of the mechanism how HOXB4 avoids leukemia in 
transplanted mice. 
 
Building on our gene expression array data, independent leukemia screening by 
Forget’s group and previous literature reports, we generated the hypothesis that 
downregulation of Prdm16 is the specific mechanism for HOXB4 to prevent leukemia in 
transplanted mice. To test the hypothesis we overexpressed HOXB4 and sPrdm16 in 
hematopoietic primitive cells and screen leukemia in the transplanted mice receiving the 
co-expressing cells. If repression of Prdm16 serves as a major factor limiting 
hematopoietic cell transformation, we expect to detect leukemia developed from HOXB4 
and sPRDM16 co-overexpressing cells. Leukemias to be detected are most likely myeloid 
leukemias. We do not expect leukemia in sPRDM16 only group because both p53 loss 
and sPrdm16 activation are required for leukemogenesis.
248
 If we did not detect any 
leukemia, it can due to the following reasons. (1) Additional genetic lesions are required 
for leukemic transformation. (2) sPrdm16 overexpression vector induces an inappropriate  
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Figure 3-1. HOXB4-mediated leukemia in transplanted mice. 
(A) Immunophenotying of bone marrow cells from recipients displaying leukemia cases 
L1 and L2. The y-axis shows the indicated cell surface markers identified by antibody 
staining and the x-axis shows GFP expression associated with the HOXB4 vector. 
Expression of mono-myeloid cell surface markers (Mac-1, CD16/32, Gr-1) and also 
erythroid (Ter119) and B lymphoid (B220) markers are shown.  A smaller percentage of 
the leukemic cells also expressed the stem cell markers c-Kit and Sca1. (B) Retroviral 
insertion sites in L2 were identified by splinkerette PCR.  The location of the 2 insertion 
sites in the adjacent to Notch1 and within Prdm16 and shown schematically along with 
the orientation of the vector at the insertion site. 
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Figure 3-2. Vector insertion site-mediated oncogene activation in HOXB4-
mediated leukemia 2 in transplanted mice. 
(A) Retroviral insertion sites in L2 identified by splinkerette PCR. The location of the 4 
insertion sites were identified in intervening sequences and 6 insertion sites were between 
genes. (B) Northern blot analysis of relevant oncogenic mRNAs from control and 
HOXB4 leukemic cells from L2. The control cells consisted of bone marrow cells of 
mice transplanted with normal BM cells transduced with the "empty" MSCV/GFP vector; 
lane labeled GFP. There is a markedly increased level of Prdm16 mRNA and a mild 
increase (~2 fold) of Notch1 mRNA in L2 BMCs compared to control BMCs. Actin 
serves as an internal loading control. 
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overexpression level of sPrdm16 or (3) repression of sPrdm16 is not the reason why 
HOXB4 doesn’t cause leukemia in transplanted mice. 
 
 
Materials and Methods 
 
 
Vector cloning 
 
The retroviral vectors MSCV-HA-HOXA9-ires-GFP and MSCV-HOXA10-ires-
GFP were kindly provided by Dr. Keith Humphries (Terry Fox Laboratory, Vancouver, 
Canada). 
 
Murine sPrdm16 cDNA (nucleotide 664-3822 of Mus musculus Prdm16 
transcript, NM_00117795) was generated by PCR using a mouse Prdm16 cDNA 
(Thermo, Clone ID 6409778) as template. The sPrdm16 cDNA was inserted into the 
CL20 MSCV-ires-mCherry lentiviral vector using EcoRI site to generate the CL20 
MSCV-sPrdm16-ires-mCherry vector. The CL20 MSCV-ires-mCherry vector was 
derived originally from pCL20c MSCV-GFP vector.
23
  
 
The CL20i4r-EF1α-HOXB4-P2A-GFP lentiviral vector was generated by PCR 
using the MSCV-HOXB4-ires-YFP retroviral vector as template. An EcoRI-HOXB4-
P2A-GFP-NotI fragment was generated by PCR and was digested with EcoRI and NotI 
and used to replace the hgcOPT fragment in CL20i4r-EF1α-hgcOPT lentiviral vector261  
 
To generate MSCV-HOXB4-ires-mCherry vector, HOXB4 cDNA was released 
from MSCV-HOXB-ires-YFP retro viral vector using EcoRI site and ligated into MSCV-
ires-mCherry lentiviral backbone between MSCV LTR and Internal ribosome entry site 
(IRES) fragment. 
 
 
Retroviral vector preparation 
 
A polyclonal ecotropic retroviral producer GPE+86 cells of MSCV-HA-HOXA9-
ires-GFP and MSCV-HOXA10-ires-GFP was generated using calcium phosphate 
transient transfection. 1 µg pCAGGS-VSVG and 5 µg old-gap-pol helper plasmids were 
co-transfected with 10 µg MSCV-HA-HOXA9-ires-GFP or MSCV-HOXA10-ires-GFP 
vector into 10x10
6
 cycling 293T cells using 50ul 2.5M calcium chloride (CaCl2) and 1x 
HBSS. Retroviral vector supernatant was harvested 48 hours post transfection, pooled, 
filtered through 0.45 µm PVDF filter (Millipore, Billerica, MA), and used to transduce 
the cycling GPE+86 cells in the presence of 5 µg/ml protamine. The transduced GFP 
positive GPE+86 cells were sorted and expanded in culture to establish stable retroviral 
vector producer lines. 
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Calcium phosphate transfection and vector concentration for lentiviral vector 
 
Six hours before transient transfection approximately 10x10
6 
HEK293T cells were 
seeded in 10-cm non-treated plates in 10ml DMEM supplemented with 10% FBS, 50 
units/ml penicillion, 50 units/ml streptomycine and 2mM L-glutamine. For production of 
10 plates of lentiviral vectors 10ug transgene containing vector, 60ug CAG-Kgp1-1, 20ug 
pCAGG-VSVG and 20ug CAG-RTR2 were mixed with water and 500ul 2.5M CaCl2 up 
to 5ml final volume. 2x HBSS was added to DNA- CaCl2 mix drop wise while vortexing. 
1ml DNA- CaCl2-HBSS mix was added into to each HEK293T plate and cells were 
incubated at 37ºC in 5% carbon dioxide. Medium was changed with 8ml X-vivo-10 for 
each plate 18 hours after transfection and supernatant containing lentiviral vector was 
harvested 42 hours post transfection. Supernatant was filtered with 0.45um low protein 
binding filter (Millipore, Billerica, MA). One day before vector concentration Beckman 
Coulter SW28 rotor, swinging buckets with centrifuge tube adaptors and rotor tubes were 
kept at 4ºC. Centrifugation tubes were sprayed with 70% ethanol and 30ml of the virus 
supernatant was added into centrifuge tube. Supernatant was spin at 25K rpm at 4ºC for 
90 minutes. As soon as spin was over, supernatant was removed and 250ul X-vivo-10 
was added to each centrifugation tube. And centrifuge tubes were kept on ice overnight. 
Next day lentiviral particles were collected, aliquot into certain volume desired and 
stored at -80ºC. 
 
 
Bone marrow cells isolation, culture and transduction 
 
Harvest and retroviral transduction of 5-FU treatment bone marrow cells were 
carried out as described in Chapter 2. 5-FU treated bone marrow cells were transduced 
with MSCV-ires-GFP, MSCV-HOXB4-ires-YFP, MSCV-HA-HOX9-ires-GFP or 
MSCV-HOXA10-ires-GFP retroviral vector, respectively. 
 
To harvest lineage-depleted bone marrow cells, whole bone marrow cells were 
isolated from 6 to 8 week old c57BL/6J mice and Lineage positive cells were depleted 
with Lineage Cell Depletion Kit, Mouse (Miltenyl Biotec) and LS columns (Miltenyl 
Biotec) according to manufacture instructions. 
 
To co-overexpress sPrdm16 and HOXB4, lineage-depleted bone marrow cells 
from 6-8 weeks-old female C57Bl/6L mice were transduced with concentrated CL20i4r-
EF1α-HOXB4-P2A-GFP and CL20-MSCV-sPrdm16-ires-mCherry vectors concurrently 
for 4 continuous days. Transduced bone marrow cells were subjected to colony forming 
assay and transplantation assay described in following paragraphs. 
 
 
In vitro expansion assay 
 
After transduction, transduction efficiency was evaluated by flow cytometry 2 
days post last transduction. The transduction efficiencies were about 50% for GFP 
control vector, 10-30% for HOXB4 vector, 20-50% for HOXA9 vector and 20-30% for 
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HOXA10 vector. For liquid culture and CFU-C assays, cells were diluted with non-
transduced cells to achieve the similar GFP percentage (about 10%), and then 5x10
5
 
normalized cells were cultured in cytokine-supplemented medium. YFP or GFP 
percentage was determined by flow cytometry and cells were counted every 3 days 
during the culture to evaluate growth advantage. 500 normalized cells cultured in M3434 
methylcellulose medium for colony forming assay. Colony replating and colony scoring 
were described in Chapter 2. 
 
For HOXB4 and sPrdm16 co-overexprssion experiment fluorescence-activated 
cell sorting (FACS) was used to sort HOXB4 and sPRDM16 double positive cells, which 
were subjected into colony forming assay in vitro. Plating of cells and colony scoring 
were described in chapter 2. 
 
 
Transplantation assay 
 
To evaluate Prdm16 expression level in GFP
+
, HOXB4
+
, HOXA9
+
 and HOXA10
+ 
primitive bone marrow cells at 6 weeks post transplantation, transplantation of transduced 
bone marrow cells were conducted as described in Chapter 2. 
 
To screen leukemia in HOXB4 and sPrdm16 co-expressing bone marrow cells 
5x10
5
 or 1x10
6 
unsorted co-transduced bone marrow cells were injected into lethally 
irradiated B6.SJL-PtprcaPepcb/BoyJ mice (Jackson Lab, stock number: 002014). 
 
 
Fluorescence-activated cell sorting  
 
To isolate each compartments of BM cells, whole BM cells were stained with 
different antibody cocktails. For CD34
-/low 
LSK cells, CD34
high
 LSK cells, CMP, GMP 
and MEP, cell were stained with CD34-PE, Sca-1-Percp5.5, c-Kit-APC, FcɛR-Alexa700 
and a PE-Cy7 conjugated lineage antibody mixture (CD4, CD8, Gr1, Ter119 and NK1.1) 
(BD Bioscience). To separate mature BM cells from each lineage, cells were stained with 
Gr1-APC-Cy7, Mac1-Alexa700, B220-FITC, CD3-APC, NK1.1-PE, and Ter119-PE-Cy7 
(BD Bioscience).  
 
To isolate LSK cells, staining was carried out in the same way described in 
Chapter 2. 
 
To isolate vector positive CD150
+
CD48
-
LSKs, CD150
+
CD48
+
LSKs and CD150
-
CD48
+
LSKs from GFP, HOXB4, HOXA9 or HOXA10 transplanted mice, bone marrow 
cells from recipients were stain with Sca1-PE (BD Bioscience) and PE-conjugated 
microbeads (Miltenyl Biotec). Sca1-PE positive cells were selected by LS column 
(Miltenyl Biotec) and further stained with CD150-PE-Cy7, CD48-APC, c-kit-APC-e780 
and lineage cocktail-e605 antibodies (BD Bioscience). 
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Stained cells were subject to FACS and each population was identified and sorted 
according to isotype and single color controls. 
 
 
Real-time PCR assay 
 
Total RNA extraction, reverse transcription and qRT-PCR assay were conducted 
as described in Chapter 2. 
 
 
Western blot 
 
Total protein lysate extraction of HOXB4 or sPrdm16 transduced NIH-3T3 cells 
and western blot were carried out as described
28
. HOXB4 protein was probed using 
0.1ug/ml I12 rat anti-mouse HOXB4 antibody (Developmental Studies Hybridoma Bank, 
University of Iowa) followed by HRP-conjugated goat anti-rat secondary antibody (Santa 
Cruz Biotechnology) and sPRDM16 protein was probed with 0.1ug/ml sheep anti-mouse 
PRDM16 polyclonal antibody (R&D systems) followed by HRP-conjugated donkey anti-
sheep secondary antibody (R&D systems). 
 
 
Immunofluorescence staining and confocal imaging 
 
Murine erythroid leukemia (MEL) cell line was transduced with MSCV-sPrdm16-
ires-mCherry vector to achieve 100% transduction efficiency. Cells transduced with 
MSCV-ires-mCherry vector were used as control. 2x10
6 
transduced MEL cells were 
plated into Retronectin (Takara) coated cover slides 48 hours after transduction for 24 
hours. Next day MEL cells were washed with 1ml warm DPBS twice gently and fixed 
with 4% paraformaldehyde at room temperature (RT) for 1hour. Cells were gently 
washed with DPBS twice before permeabilized with 0.1% triton100 in DPBS for 15 mins 
at RT. After permeabilization cells were treated with Image-it TX signal enhancer 
(Invitrogen) for 30 mins at RT. Cells were stained with 10ug/ml sheep anti-mouse 
PRDM16 polyclonal antibody (R&D systems) in DPBS containing 10% normal donkey 
serum (Sigma) at 4 ºC overnight. Cells were washed by ice cold DPBS for 5 mins for 
three times next day before incubation with donkey-anti-sheep Alexa488 at 1:100 
dilution in DPBS with 10% normal donkey serum at RT for 1hour. Cells were rinsed with 
DPBS 3 times for 5mins each and stained with DAPI for 10 mins at RT and further rinsed 
with DPBS and were mounted for confocal image capture with Zeiss LSM 510 confocal 
microscope.  
 
 
Southern blot 
 
NIH-3T3 cells were transduced with CL20-MSCV-sPrdm16-ires-mCherry vector 
to achieve ~60% transduction efficiency. Mock or CL20-MSCV-ires-mCherry control 
vector transduced cell were used as control. Genomic DNA was extracted with 
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ArchivePure DNA Cell/Tissue kit (5 PRIME). 10ug genomic DNA was digested with 40 
unites of DraI (NEB) at 344bp upstream of rev response element (RRE) and 102bp 
downstream of mCherry element to release 7.18kb fragment. Genomic DNA migrated in 
0.8% agarose gel at 20V overnight, was transferred to Nytran SPC membrane (Fisher 
Scientific) and was hybridized dCTP-P32 labeled probe fragment complementary to RRE 
at 42ºC overnight. Blot was washed and image was scanned next day. 
 
 
Results 
 
 
Endogenous Prdm16 expression in LT-HSC and ST-HSCs 
 
The endogenous Prdm16 expression pattern consists of relatively high expression 
in CD34
-/low
Sca1
+
c-kit
+
Lin
-
 long term hematopoietic stem cells (LT-HSCs) and to a lesser 
extent in CD34
high
Sca1
+
c-kit
+
Lin
- 
short term HSC cells (ST-HSCs) (Figure 3-3). 
Endogenous expression levels were about 120 fold higher in LT-HSCs than in total bone 
marrow cells. Prdm16 mRNA was down-regulated in myeloid and lymphoid progenitors 
at various stages of development as well as in mature blood cell lineages (Figure 3-3). 
These results showed that Prdm16 expression is largely restricted to LT-HSCs where 
Prdm16 is required for HSC maintenance and function
215,216
. 
 
 
Overexpression of HOXA9 and HOXA10 led to growth advantage and enhanced 
colony forming capacity in vitro 
 
To exam whether overexpression of HOXA9 or HOXA10 was able to expand 
hematopoietic progenitors and enhance their self-renewal capacity in vitro, we transduced 
5-FU treated bone marrow cells with retroviral vector containing either HOXA9 or 
HOXA10 cDNA. Cells overexpressing HOXB4 were included as positive control and 
control GFP transduced cells as negative control. During 15 days’ culture HOXB4, 
HOXA9 and HOXA10 expressing cells showed significant grow advantage over control 
transduced cells. GFP or YFP percentage of HOXB4, HOXA9 or HOXA10 increased 
from about 10% to 85.87%, 93.83% and 96.47%, respectively (Figure 3-4A). Colony 
forming capacity was also enhanced in HOXB4, HOXA9 and HOXA10 expressing cells 
(Figure 3-4B). 
 
 
Prdm16 is not expressed in cultured LSKs 
 
Endogenous Prdm16 was shown to be highly expressed in WT murine LT-HSC 
and ST-HSC in previous experiment. We also assessed Prdm16 transcript level in 
HOXB4, HOXA9 and HOX10 transduced LSK cells at day 4, 8 and 13 days post 
transduction in vitro. Compared with WT LSK cells, there wasn’t detectable Prdm16 
transcript in GFP control transduced LSK cells in vitro and overexpression of HOXB4,  
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Figure 3-3. Quantitative real-time PCR of endogenous Prdm16 mRNA levels in 
various sorted progenitor and stem cell populations. 
Endogenous Prdm16 was highly expressed in LT-HSCs and maintained relative high 
expression level in ST-HSCs. No or low level of Prdm16 transcript was detected in 
downstream progenitors and mature cells in bone marrow. Gapdh mRNA was used as a 
loading control and the level of Prdm16 mRNA expression in whole bone marrow was 
set at a relative value of 1.0. CMP: common myeloid progenitor; GMP: granulocyte-
monocyte progenitor; MEP: magakarocyte-erythroid progenitor. 
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Figure 3-4. Growth advantage and enhanced myeloid progenitor self-renewal 
observed in HOXB4, HOXA9 and HOXA10 transduced cells in vitro. 
(A) HOXB4, HOXA9 and HOXA10 demonstrated significant growth advantage over 
GFP control transduced cells during 15 days’ culture. (B) HOXB4, HOXA9 and 
HOXA10 generated significant more secondary colonies than untransduced or GFP 
transduced cells. HOXA9 and HOXA10 demonstrated more robust colony forming 
capacity than HOXB4. 
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HOXA9 and HOXA10 were not able to alter Prdm16 expression as they did in 
transplanted mice (Figure 3-5). 
 
 
Prdm16 downregulation is restricted to HOXB4-expressing HSCs in vivo 
 
HSC positive regulator, Prdm16, was downregulated in HOXB4-LSKs during the 
reconstitution, suggesting downregulation of Prdm16 can be a counter-regulatory signal 
which controlls HSC pool size or prevents leukemia in vivo. HOXA9 and HOXA10 are 
known oncogene, overexpression of which causes unlimited HSC expansion and 
leukemia in transplanted mice. We compared Prdm16 expression level in HOXB4, 
HOXA9 or HOXA10 expressing CD150
+
CD48
-
LSKs (SLAM), CD150
+
CD48
+
LSKs and 
CD150
-
CD48
+
LSKs (restricted progenitors) in transplanted mice at 6 weeks post 
transplantation. Compared with control GFP-SLAMs, Prdm16 was 13.5 fold 
downregulated in HOXB4-SLAMs, but 5 fold upregulated in HOXA9-SLAM and 1.8 
fold upregulated in HOXA10-SLAMs (Figure 3-6). Both HOXA9-SLAMs and 
HOXA10-SLAMs showed opposite trend of Prdm16 expression compared to HOXB4-
SLAMs (Figure 3-6), indicating HOXB4 specifically downregulates Prdm16 to limit 
HSC pool size or to prevent leukemia. At meanwhile Prdm16 expression level was not 
detachable in CD150
+
CD48
+
LSKs and CD150
-
CD48
+ 
LSKs in all groups (Figure 3-6), 
suggesting HOXB4 specific downregulation of Prdm16’s was restricted in HSC 
compartment but not in downstream differentiated compartments. 
 
 
Lentiviral sPrdm16 construct and sPRDM16 protein expression  
 
To overexpress HOXB4 and sPRDM16 in mouse bone marrow cells, we 
generated lentiviral vector containing either HOXB4 with a GFP reporter gene driven by 
Ef1α promoter or sPrdm16 with a linked mCherry gene downstream of MSCV promoter 
(Figure 3-7A). Western blot of vector transduced NIH-3T3 cells confirmed robust 
expression of HOXB4 and sPRDM16 protein (Figure 3-7B) and sPRDM16 protein was 
localized in nucleus when overexpressed in MEL cell line (Figure 3-7C). 
 
 
Low transduction efficiency of sPrdm16 overexpression vector 
 
To generate HOXB4 and sPRDM16 co-expressing cells, Lin
-
 cells were 
transduced with HOXB4 and sPrdm16 vectors concurrently for 4 days (Figure 3-8A). 
Transduction efficiency of the bone marrow cells was evaluated 5 days post last 
transduction. We observed low proportion of cells expressing sPRDM16-mCherry 
protein (Figure 3-8B).  
 
We followed sPrdm16-mCherry marking of transduced WT and p53 null cells in 
culture for up to 20 days post transduction. Rapid depletion of sPrdm16-mCherry positive 
WT and p53 null cells was detected as early as 4 days post transduction (Figure 3-9A). 
Depletion of sPRDM16 expressing cells could be due to cellular toxicity caused  
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Figure 3-5. Relative Prdm16 expression in HOXB4, HOXA9 and HOXA10 
transduced LSKs in vitro. 
Prdm16 transcript was measured in GFP, HOXB4, HOXA9 or HOXA10 transduced 
LSKs 4 days, 8 days and 13 days after transduction. Prdm16 transcript was not detected 
in cultured LKSs in vitro compared with wild type LSKs. Gapdh mRNA was used as an 
endogenous control and the level of Prdm16 mRNA expression wild type LSKs was set 
at a relative value of 1.0. 
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Figure 3-6. Downregluation of Prdm16 is restricted in HOXB4 expressing HSCs 
in vivo. 
Prdm16 expression in HOXB4-SLAM was downregulated while upregulated in HOXA9-
SLAM and HOXA10-SLAM at 6 weeks post transplantation. Expression of Prdm16 was 
not expressed in CD150
+
CD48
+
LSKs and CD150
-
CD48
+
 LSKs in all groups. Gapdh 
mRNA was used as an endogenous control and the level of Prdm16 mRNA expression 
wild type LSKs was set at a relative value of 1.0. 
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Figure 3-7. Lentiviral vectors engineered to overexpress sPrdm16 and HOXB4. 
(A) Schematic representation of lentiviral vectors to overexpress HOXB4 and sPrdm16. 
The promoters and fluorescent reporter genes used are indicated. The 400bp chromatin 
insulator (i4r) was used as indicated to protect from position effects. (B) Western blot 
analysis of HOXB4 and sPrdm16 expression in NIH-3T3 cells transduced with the 
indicated vectors. Note the lower background band seen on the sPrmd16 blot is also 
present with the “empty” vector control. (C) Immunofluorescence staining of sPrdm16 
protein in MEL cell line.sPrdm16 protein was expressed in the nucleus. Green: sPrdm16; 
Blue: Dapi 
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Figure 3-8. Low transduction of sPrdm16 vector in murine bone marrow cells. 
(A) Concurrent transduction includes 4 days transduction with two vectors 
simultaneously on Lin
-
 bone marrow cells followed by FACS-based sorting 2 days after 
transduction. (B) Low co-transduction efficiency of sPrdm16 vector with GFP control 
vector or HOXB4 vector on BM cells evaluated 5 days post transduction. 
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Figure 3-9. Depletion of sPRDMdfdf16 expressing cells was not due to vector 
rearrangement. 
(A) GFP or mCherry marking of bone marrow cells in culture starting from 2 days post 
transduction. Experiment was done on either WT or P53 null mice. (B) Southern blot of 
NIH-3T3 cells transduced with CL20-MSCV-sPrdm16-ires-mCherry. CL20-MSCV-
sPrdm16-ires-mCherry plasmid was used as positive control. 
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by unphysiologically high sPRDM16 protein level or vector instability during vector 
genome integration. So we tested sPrdm16 vector rearrangement in transduced NIH-3T3 
cells by southern blot. Compared with plasmid control, no rearrangement and deletion 
occurred between RRE and mCherry fragment in sPrdm16-mcherry transduced sample 
(Figure 3-9B), suggesting reduced sPrdm16-mcherry marking in bone marrow cells was 
not due to vector rearrangement. 
 
 
Increased colony forming capacity of HOXB4 and sPRDM16 coexpressing cells 
 
To test whether sPRDM16 and HOXB4 cooperate to enhanced hematopoietic 
progenitor cell self-renewal in vitro. Single and double transduced cells were sorted by 
flow sorting and analyzed for myeloid progenitor self-renewal using a serial replating 
assay. Cells transduced with the HOXB4 vector alone formed about 160 secondary 
colonies per1x10
4
 cells plated while sPrdm16-transduced cells formed about 70 
secondary colonies (Figure 3-10). The HOXB4 and sPRDM16 double positive group 
formed over 300 secondary colonies, significantly more than the HOXB4 only group 
(p<0.01) (Figure 3-10). This result demonstrates that HOXB4 and sPRDM16 synergize 
to enhance hematopoietic progenitor cell self-renewal. 
 
 
Enforced co-expression of sPRDM16 and HOXB4 causes preleukemia in mice 
 
We also transplanted co-transduced bone marrow cells into lethally irradiated 
recipient mice. Reconstitution with cells expressing the sPrdm16 vector was generally 
very low, presumably reflecting the low titer of this vector or direct toxic effects of 
enforced sPrdm16 expression. However, a large number of HOXB4 and sPrdm16 double 
positive cells were detected in the peripheral blood in 2 of 12 recipients at 12 weeks after 
transplantation. In these two cases (#890 and #894), expansion of HOXB4 and sPrdm16 
double positive blood cells occurred as early as 6 weeks after transplantation and further 
increased over time. When mouse #894 was euthanized at 12 weeks post transplantation, 
52.8 % of peripheral blood cells and 97.1% of bone marrow cells co-expressed the 
HOXB4 and sPrdm16 as determined by flow cytometry (Figure 3-11A). These double 
positive cells showed the Gr-1
+
, Mac-1
+
 myeloid phenotype.  
 
Bone marrow cells from mice #890 and #894 were used for secondary 
transplantation experiments. Secondary recipients from case #894 did not engraft with 
donor cells.  In contrast, secondary recipients generated from #890 (#10037, #10038 and 
#10040) were all repopulated with HOXB4 and sPrdm16 co-expressing cells in 
peripheral blood and bone marrow. At 12 and 16 weeks after transplant, pathological 
examination revealed prominent myeloid dysplasia with increased myeloid blasts in the 
bone marrow; consistent with myelodysplasia and pre-leukemia (Figure 3-11B). Taken 
together, this experiment directly shows that HOXB4 and sPrdm16 overexpression 
collaborate to promote preleukemia in a fraction of secondary transplant recipients. 
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Figure 3-10. Secondary colony numbers by myeloid CFU-C assay on sorted 
transduced cells as a measure of self-renewal capacity. 
Cells were transduced with control vectors or mock transduced, or with single HOXB4 or 
sPrdm16 vectors, or co-transduced with both HOXB4 and sPrdm16 vectors as indicated. 
After a primary CFU-C assay, cells were replated and colonies scored based on 10,000 
cell inputs. Error bars show the standard deviation for multiple experiments and statistical 
comparisons are indicated above the histograms. 
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Figure 3-11. Enforced co-expression of HOXB4 and sPrdm16 enhances HPC self-
renewal in vitro and induces myeloid pre-leukemic transformation in transplanted 
mice. 
(A) Flow cytometry analyses of HOXB4 and sPrdm16 double positive cells in peripheral 
blood (PB) and bone marrow cells (BMC) of two primary recipients, # 890 and # 894. 
The top row shows staining for the donor background CD45.1, the middle row shows 
expression of the sPrdm16 vector marker (mCherry) and the HOXB4 vector marker 
(GFP), and the last row shows expression of the Mac-1 and Gr-1 myeloid markers. Note 
the expansion of double positive myeloid cells in each of these cases. (B) Bone marrow 
cytospin photomicrographs of secondary recipients (#10037 and #10040) derived by 
transplantation from donor #890. Insets show higher magnification of the myeloid blasts 
seen in these cases, which comprised 30-50% of the cells on these slides. 
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Discussion 
 
Our gene expression array data from HOXB4 expressing LSK cells demonstrated 
marked downregulation of Prdm16. By reviewing previous literature and independent 
screening of HOXB4 transplanted mice, we hypothesized that downregulation of Prdm16 
is the specific mechanism how HOXB4 prevent leukemia in transplanted mice. Here we 
talk about ‘HOXB4-specific mechanism’ because HOXA9 and HOXA10, oncogenic 
HOX factors, upregulated Prdm16 expression up to about 50 fold in HSCs compared 
with HOXB4. Differential regulation of Prdm16 by HOXB4, HOXA9 and HOXA10 was 
not seen in culture, as Prdm16 expression was no longer detectable in vitro, suggesting 
extrinsic factors present in bone marrow niche are required to maintain Prdm16 
expression in HSCs. However, there are no available methods for phenotypically 
identifying HSCs in these long term cultures. While we gated on LSK cells after various 
times in culture, published data
262,263
 suggests that these markers, or any other for that 
matter, are not adequate for prospective identification of HSC-enriched populations in 
vitro.  
 
To further validate that downregulation of Prdm16 is responsible for preventing 
leukemic transformation in HOXB4 transplanted mice, we can co-overexpressed HOXB4 
and sPRDM16 in murine primitive bone marrow cells to induce leukemia. At meanwhile 
knockdown Prdm16 in HOXA9 or HOXA10 transplanted mice prior or after leukemia 
onset will be anther experiment to test sustained expression of Prdm16 as a major player 
in leukemogenesis. But this part of experiment will not be included in this project. 
 
We designed lentiviral vectors to overexpress HOXB4 and sPRDM16 in murine 
hematopoietic primitive cells. HOXB4 and sPRDM16 protein expression was confirmed 
in transduced NIH-3T3 cells. However, we noticed very low (less than 5%) co-
transduction efficiency of sPrdm16 with control GFP vector and HOXB4 vector. This 
may reflect the low titer of the sPrdm16 vector. But it also can be due to vector 
rearrangement during integration. Southern blot done on sPrdm16 transduced NIH-3T3 
cells detected intact transgene fragment, excluding the possibility of vector 
rearrangement. As mentioned above, Prdm16 is selectively expressed at high level in 
HSCs. sPRDM16 expression level of by overexpression vector probably was not 
favorable in transduced progenitor cells in culture. This explains why Prdm16 was not 
detectable in culture cells and marked decreased proportion of Prdm16 transduced cells in 
vitro. 
 
Though low transduction of Prdm16 vector makes it difficult to overexpress 
Prdm16 using constitutive overexpressing vector, we were able to purify 500 double 
transduced cells for colony forming assay to test both factors’ effect on the self-renewal 
capacity of myeloid progenitors. We injected bulk transduced cells for transplantation 
assay to screen leukemia in mice due to inadequate mount of double cells for 
transplantation. Since we hypothesize that downregulation of Prdm16 prevents 
leukemogenesis inHOXB4 transplanted mice, we expect leukemia derived from only 
HOXB4 and sPrdm16 double positive cells but not any other populations. We detected 
two preleukemia cases (myeloid dysplasia) out of 12 primary recipients at 28 weeks and 
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32 weeks following primary transplantation. Long latency of leukemogenesis reflects the 
low number of leukemia initiating cells due to the poor co-transduction efficiency or the 
requirement of additional mutations for the leukemic transformation. The mechanisms by 
which sPrdm16 cooperates with HOXB4 are yet undefined. Expression of sPRDM16 
blocks granulocyte-colony stimulating factor (G-CSF)-induced myeloid 
differentiation
198,238,239
 and over-expression of sPRDM16 in mice causes a 
myeloproliferative disorder and leukemia in p53-null bone marrow cells.
248
 Therefore, in 
the context of HOXB4-induced HSC expansion, downregulation of Prdm16 functions to 
induce hematopoietic differentiation, thus preventing leukemia in vivo. 
 
To address the low transduction efficiency of sPrdm16 lentiviral vector, TetOn 
inducible vector which is able to activate transgene expression upon doxycycline 
induction at dose-dependent manner can be a great replacement of constitutive 
overexpression vector. We decide to establish TetOn-sPrdm16 transgenic mouse to 
further study the role of Prdm16 in HSC expansion and leukemogenesis. The advantage 
of transgenic mouse over the vector transduction is the stable and predictable transgene 
integration rather than random vector integration between one transduction and another. 
We plan to transplant sPrdm16 transgenic bone marrow cells into wild type recipients to 
avoid side effect of sPRDM16 overexpression in other organs. 
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CHAPTER 4.    DOWNREGULATION OF PRDM16 IS REQUIRED FOR 
HOXB4-MEDIATED HSC EXPANSION 
 
 
Introduction 
 
In previous chapter downregulation of Prdm16 was shown as HOXB4-specific 
mechanism to prevent leukemia in transplanted mice. Besides avoiding leukemic 
transformation, well-regulated HSC pool size in HOXB4 recipient mice is another feather 
of HOXB4-mediated HSC expansion,
141,181,182
 mechanism of which is not clear. 
Induction of differentiation, apoptosis or quiescence in HSCs post dramatic proliferation 
can contribute to maintain HSC pool size at physiological level. Prdm16 is selective 
expressed in LT-HSCs.
215,216
 Sustained expression of Prdm16 HSCs can maintain HSC’s 
quiescence, and loss of Prdm16 may drive HSC into cell cycle, thus allowing 
proliferation and expansion. Given the fact that loss of Prdm16 indeed increased the 
frequency of HSCs in S/G2/M phase of the cell cycle,
215,216
 and Prdm16 was markedly 
repressed by HOXB4 in vivo, we hypothesize that HOXB4 downregulates Prdm16 to 
allow HSC to undergo proliferation. To test the hypothesis we will assess CRU frequency 
in HOXB4 transplanted mice present or absent of sPrdm16 overexpression. Considering 
the poor transduction of sPrdm16 lentiviral vector, we will generate TetOn-sPrdm16 
transgenic mice, bone marrow of which will be used for experiments. We expect 
sPRDM16 protein expression upon doxycycline administration in transgenic bone 
marrow cells and lower CRU frequency in HOXB4 and sPRDM16 coexpressing cells 
than HOXB4 only expressing cells. 
 
 
Materials and Methods 
 
 
Vector cloning 
 
To generate TetOminiCMV-sPrdm16-P2A-GFP-rGBpA vector, sPrdm16 cDNA 
was released from MSCV-sPrdm16-ires-mCherry vector using EcoRI and replaced in 
front of HOXB4 cDNA in EF1a-HOXB4-P2A-GFP vector to generated EF1a-sPrdm16-
HOXB4-P2A-GFP vector. Synthesize partial sPrdm16-P2A fragment was generated by 
Biomatik with DraIII in 5’end and BsmBI in the 3’ end, which was replaced with partial 
sPrdm16-HOXB4-P2A fragment in EF1a-sPrdm16-HOXB4-P2A-GFP vector. In the end 
Ef1a-sPrdm16-P2A-GFP vector was established. Fragment sPrdm16-P2A-GFP was 
further released from backbone with EcoRI and NotI and EcoRI site in the 5’ end was 
blunted using Klenow. Lentiviral vector pHAGE2-TetOminiCMV-Oct4F2AKlf4-ires-
Sox2E2AcMyc-W was offered by Charles Sherr in St. Jude Children’s Research 
Hospital. Fragment Oct4F2AKlf4-ires-Sox2E2AcMyc was removed from backbone 
using NotI and ClaI and NotI site present in backbone was blunted by Klenow. sPrdm16-
P2A-GFP fragment was ligated into the pHAGE2-TetOminiCMV backbone to generate 
pHAGE2-TetOminiCMV-sPrdm16-P2A-GFP lentiviral vector. rGBpA fragment was 
amplified by PCR from Prdm16 knockdown vector and further digested by HindIII to 
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release the exact rGBpA fragment. Previous generated pHAGE2-TetOminiCMV-
sPrdm16-P2A vector was digested with NotI and blunted by Klenow. HindIII digested 
rGBpA was also blunted by Klenow and replaced into pHAGE2-TetOminiCMV-
sPrdm16-P2A after P2A fragment to generate pHAGE2-TetOminiCMV-sPrdm16-P2A-
rGBpA vector. pHAGE2-TetOminiCMV-sPrdm16-P2A-rGBpA circular vector was 
digested by XhoI and NotI to release linearized TetOminiCMV-sPrdm16-P2A-rGBpA 
for microinjection.  
 
CMV-rtTA lentiviral vector was kindly provided by Dr. Charles Sherr in St. Jude 
Children’s Research Hospital.  
 
 
Calcium phosphate transfection and vector concentration for lentiviral vector 
 
Calcium phosphate transfection and ultracentrifugation of TetOminiCMV-
sPrdm16-P2A-GFP lentiviral vector were carried out in the same way described in 
Chapter 3. 
 
 
sPRDM16 protein induction in vitro 
 
Prior to microinjection of linearized plasmid to mice zygotes, NIH3T3 cells were 
co-transduced with TetOminiCMV-sPrdm16-P2A-GFP and CMV-rtTA lentiviral vectors. 
48 hours post transduction, NIH3T3 cells were treated with 0ng/ml, 0.1ng/ml, 1ng/ml, 
10ng/ml, 100ng/ml and 1000ng/ml of doxycycline for 48 hours and doxycycline was 
withdrew from medium. GFP fluorescence was evaluated by flow cytometery after 48 
hours’ induction and 5days’ withdraw and protein expression was examined by western 
blot after 48 hours’ induction. 
 
 
Mouse strain maintenance and breeding 
 
All mouse maintenance and breeding procedures were carried out according to 
protocols approved by the St. Jude Institutional Animal Care and Use committee. 
Transgenic founder mice were bred with B6.Cg-Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J 
mice (Jackson Lab, stock number 006965) to generate N1 mice carrying both transgene 
and rtTA knockin gene and then further bred with B6.Cg-
Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J mice to generate rtTA homozygote transgenices. 
 
 
Polymerase chain reaction (PCR) genotyping 
 
To confirm the presence of transgene in the genome of progenies, PCR to amplify 
the fragment between sPrdm16 cDNA and green fluorescence protein (GFP) was used for 
genotyping. Genomic DNA was extracted from tails and about 10ng of genomic DNA 
was subjected to PCR with HotMaster Mix (5 PRIME). PCR primer sequences were 
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GCTGGAGGAAGAGGATGATG (forward) and GAACTCCAGCAGGACCATGT 
(reverse) and expected PCR product size was 892bp. At meanwhile PCR to amplify 
endogenous Actin was carried out as control reaction. 
 
To confirm presence of rtTA knockin sequence in the genome of progenies, PCR 
was carried out according to Jackson Lab’s instruction. Mutant reverse primer 
oIMR8052-- GCG AAG AGT TTG TCC TCA ACC, WT reverse primer oIMR8546-- 
GGA GCG GGA GAA ATG GAT ATG and common primer oIMR8545-- AAA GTC 
GCT CTG AGT TGT TAT were used for genotyping. Expected size of WT product is 
about 650 bps, size of rtTA heterozygote is 340bp and 650bp and rtTA homozygotes is 
340bp. 
 
No template control and WT control were included for both PCR reactions. 
 
 
Doxycycline drinking water administration 
 
To induce transgene expression in vivo, transgenic mice or transplanted mice 
were subjected to 2mg/ml doxycycline (Sigma) treatment in drinking water with 
50mg/ml sucrose (Sigma). Drinking water without doxycycline was used as control. 
Drinking water was filtered with Corning disposable sterile filter system (Corning) and 
changed every 3 days.  
 
 
Western blot 
 
PCR positive transgenic mice and control littermates were under 2mg/ml 
doxycycline treatment for continuous 7days. GFP positive and negative BM cells were 
sorted. 1x10
6 
sorted cells were washed with 1ml ice cold DPBS, resuspended with 50ul 
ice cold DPBS with 2x Halt Protease Inhibitor Cocktail with EDTA (Thermo Scientific 
Pierce) and 50ul Laemmli sample buffer (Bio-Rad) supplemented with 2-
Mercaptoethanol (Sigma) and boiled at 99 ºC for 5 minuts before being placed on dry ice. 
40ul cell lysate (from 4e5 cells) were load in 4%-12%SDS-PAGE gel (Invitrogen) for 
protein detection. sPRDM16 protein was probed with 0.1ug/ml sheep anti-mouse 
PRDM16 polyclonal antibody (R&D systems) followed by HRP-conjugated donkey anti-
sheep secondary antibody (R&D systems). GFP protein was probed with rabbit GFP 
antibody (Cell signaling) at 1:5000 dilution followed by HRP-conjugated goat anti-rabbit 
secondary antibody (Santa Cruz Biotechnology). GAPDH protein was probed with 
mouse anti-mouse GAPDH antibody (Millipore) at 1:50000 dilution followed by HRP-
conjugated goat anti-mouse IgG1 antibody (Santa Cruz Biotechnology). 
 
 
Southern blot 
 
About 3-10ug tail genomic DNA was digested with sphI-HF in 40ul reaction at 37 
ºC for 8 hours to check transgene copy number or digested with DraI and PshAI to check 
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transgene integrity. DNA gel electrophoresis, transfer and hybridization and image 
detection was carried as described in chapter 3. The probe used for hybridization was 
complementary to GFP sequence.  
 
 
Fluorescence in situ hybridization (FISH) 
 
Bone marrow cells from transgenic mice were submitted to Cytogenetic Shared 
Resource of St. Jude Children’s Research Hospital to determine integration localization 
of transgene by FISH. Purified TetOminCMV-sPrdm16-P2A-GFP-rGBpA plasmid DNA 
was labeled with a green-dUTP by nick translation and chromosome control clone was 
labeled with a red-dUTP. Labled probes were combined with sheared mouse DNA and 
hybridized to matophase chromosomes derived from the bone marrow cells. The 
chromosomes were stained with DAPI and analyzed.  
 
 
Fluorescence flow cytometry analysis 
 
To detect phonotypical HSC and MPP frequency in transplanted mice, bone 
marrow cells were stained with CD150-PE-Cy7, CD48-APC, Sca-1-Percp5.5, c-Kit-
APC-eF780, CD45.2-V500 and eF605 conjugated-lineage cocktail (BD Bioscience). 
SLAM (CD150
+
CD48
-
Sca-1
+
c-Kit
+
Lineage
-
) and MPP (Sca-1
+
c-Kit
-
Lineage
-
) population 
were gated according to isotype and single color controls. 
 
 
Limiting dilution assay 
 
For limiting dilution assay to assess CRU frequency, BM cells of transgenic mice 
were harvested 5 days after 5-FU treatment, prestimulated as describe in chapter 2. After 
prestimulation 5x10
5
 bone marrow cells were transduced with MSCV-HOXB4-ires-
mCherry vector overnight. Control vector MSCV-ires-mCherry vector was included as 
control. Next day after transduction 5x10
5
 or 1x10
6
 were injected into lethally irradiated 
B6.SJL-PtprcaPepcb/BoyJ mice (Jackson Lab). Recipients were under Baytril water 
treatment for 3 weeks followed by doxycycline (2mg/ml) treatment. Drinking water 
without doxycycline was used as control. Bone marrow cells were harvested from 
primary recipients at 18 weeks post transplantation and 320, 1600, 8000, 4x10
4
 and 2x10
5
 
bone marrow cells were injected into letherally irradiated B6.SJL-PtprcaPepcb/BoyJ mice 
(Jackson Lab) together with 2x10
5 
B6.SJL-PtprcaPepcb/BoyJ (Jackson Lab) bone 
marrow cells. Recipients’ PB was analyzed 18 weeks post secondary transplantation. 
Mouse with more than 1% mCherry marking in each lineage (Gr1 and Mac1, CD3, B220, 
Ter119) was considered as a positive recipient. CRU frequency was calculated using L-
Calc
TM
 software (Stemsoft Sotfware Inc. version 1.1). 
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Results 
 
 
Vector construction 
 
We generated lentiviral vector to overexpress murine sPrdm16 driven by 
TetOminiCMV promoter followed by P2A-GFP (Figure 4-1A). For microinjection to 
generate TetOminiCMV-sPrdm16-P2A-GFP-rGBpA transgenic mice, rBGpA fragment 
was ligated into vector after GFP. Linearized TetOminiCMV-sPrdm16-P2A-GFP- 
rGBpA DNA fragment (Figure 4-1A) was injected in fertilized zygotes at singe cell 
stage. 
 
 
Dose-dependent induction of sPRDM16 and GFP protein 
 
NIH-3T3 cells were co-transduced with TetOminiCMV-sPrdm16-P2A-GFP and 
CMV-rtTA vectors (Figure 4-1A) and further induced by 0-1000ng/ml doxycycline for 
48 hours in vitro. 0ng/ml, 0.1ng/ml and 1ng/ml doxycycline did not induce significant 
GFP expression (baseline), 10ng/ml doxycycline led to mediate GFP induction while 
100ng/ml and 1000ng/ml doxycycline achieved maximum induction of GFP expression 
(Figure 4-1B). GFP expression decreased to baseline 5 days after doxycycline was 
withdrew (Figure 4-1B). sPRDM16 and GFP protein was detected in 10ng/ml, 100ng/ml 
and 1000ng/ml samples 48 hours after induction by western blot, which was consistent 
with GFP fluorescence signal by flow cytometry (Figure 4-1C). sPRDM16 and GFP 
protein expression showed nice linear correlation (Figure 4-1C). Both protein inductions 
were maximized at dose of 100ng/ml without no further increase of protein expression at 
1000ng/ml doxycycline (Figure 4-1C).  
 
 
Generation and validation of TetO-sPrdm16 transgenic mice 
 
To achieve inducible sPRDM16 protein expression in mouse bone marrow cells, 
we generated TetO-sPrdm16 transgenic mice. Transgenic founder mice carrying one 
allele of transgene was bred with B6.Cg-Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J mice 
(Jackson Lab, stock number 006965) to generate N1 mice, which were able to expression 
sPRDM16 protein under doxycycline induction (Figure 4-2). N1progenies were further 
bred with rtTA*M2 mice to achieve two allele of rtTA gene in genome. 
 
PCR amplifying the transgene region was carried out on mouse tail genomic DNA 
to check the presence or absence of transgene in mouse genome. PCR primers were 
designed to amplify between sPrdm16 and GFP region to yield 892bp product as shown 
in lane 1, 5, 9, 11 and positive control (Figure 4-3A, B). Total 21 PCR positive 
transgenic founders were identified, 7 of which were c57BL/6J strain and others were 
FVB strain. PCR were carried out on N1 genomic DNA and 17 out of 21founders had 
germline transmission to N1 and following progenies. PCR was carried out according to 
Jackson Lab’s instruction to detect WT, heterozygotes and homozygotes of rtTA gene.  
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Figure 4-1. Dose-dependent induction of sPRDM16 and GFP protein with TetOn 
inducible system. 
(A). Schematic diagram of TetOminiCMV-sPrdm16-P2A-GFP and CMV-rtTA lentiviral 
vectors and linearized TetOminiCMV-sPrdm16-P2A-GFP-rBGpA. (B) GFP fluorescence 
detected in transduced NIH-3T3 cells 48 hours post Doxcycline induction and decreased 
back to baseline 5 days after Doxycycline withdraw.(C): sPRDM16 and GFP protein was 
detected in induced NIH-3T3 cells at dose of 10, 100 and 1000ng/ml Doxycycline after 
48 hours’ induction. 
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Figure 4-2. Schematic diagram of TetO-sPrdm16 transgenic mice generation. 
Transgenic founder mice were Bred with B6.Cg-Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J 
mice to generate N1 mice carrying both transgene and rtTA knockin gene.  
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Figure 4-3. TetO-sPrdm16 transgenic mice PCR genotyping. 
(A). Forward and reverse primers designed to amplify partial sPrdm16-P2A-GFP region 
to detect presence of transgene in mouse genome. (B). Example of sPrdm16 transgene 
PCR genotyping. Lane 1, 5, 9 and 11 are transgene positive compared with non-template 
control (NTC), wild type (WT) control and positive control (P.C). (C). Example of rtTA 
knockin gene PCR genotyping. Compared with NTC, WT and rtTA
+/+ 
control, lane 1 and 
2 are rtTA
+/-
 and lane 3-7 are rtTA
+/+
. 
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Expected size of WT product is about 650 bps (WT control lane), size of rtTA 
heterozygote is 340bp and 650bp (lane 1 and 2) and rtTA homozygotes is 340bp (lane 3-
7) (Figure 4-3C). 2mg/ml Doxycycline in drinking water was given to three litters of N1 
mice with germline transmission for 7 days to detect GFP fluorescence in nucleated cells 
from PB.by flow cytometry. 9 out of 17 founders’ N1 progenies demonstrated inducible 
and reversibl GFP expression in PB with different level of GFP induction efficiency 
(Figure 4-4A, B). 
 
To check transgene copy number and integrity in mouse genome, southern blot 
was carried out on founders (8012, 8005, 8080, 8018 and 8017) and progenies with the 
best GFP induction. Southern blot of founder 8012, 8080, 8018 and 8017 showed single 
copy of transgene with one integration in mouse genome while founder 8005 had more 
than one integration and more than one copy of transgene (Figure 4-5A). We also 
detected rearranged or deletion of transgene from 8005 genome (Figure 4-5A). To 
segregate rearranged or deleted transgene we further bred 8005 with B6.Cg-
Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J mice and carried out southern blot on four N1 
progenies (8096, 8098, 8100 and 8219) of founder 8005. Only one copy of transgene 
with one integration was detected in 8098 and 8219 (Figure 4-5B) and no rearrangement 
or deletion detected in 8098 progenies (8489, 8491 and 8493) (Figure 4-5C). We named 
the transgenic line established from founder 8005 with on copy of transgene as 8005S. 
Finally we generated three independent TetO-sPrdm16 transgenic lines: 8012 8005S 
(with one copy, no rearrangement) and 8080. 
 
To further identify transgene localization, bone marrow cells from each transgenic 
line was submitted for FISH. Integration site of transgene in 8012 line was chromosome 
19B-C1 region, chromosome 3C-D region for 8005S line and chromosome 2C-1 region 
in for 8080 line (Figure 4-6A). 
 
Western blot was carried out on transgenic bone marrow cells to detect sPRDM16 
and GFP protein expression. PCR positive transgenic mice and litter mate control were 
under 2mg/ml doxycycline induction for 7 days. Sucrose water without doxycycline was 
used as control. Due to incomplete induction in bone marrow cells, GFP positive cells 
were sorted for western blot to increase the sensitivity. Singlets from control bone 
marrow cells were also sorted for protein detection. sPRDM16 and GFP were only 
expressed in transgenic bone marrow cells under doxycycline induction while sPRDM16 
and GFP was not detected in control (Figure 4-6B) WT bone marrow cells in the 
presence or absence of doxycycline as well as non-induced transgenic bone marrow cells 
(Figure 4-6B). This result indicates specificity of gene induction and protein expression 
in TetO-sPrdm16 transgenic mice.  
 
Transgenic mice from 8012 line were under doxycycline induction for 39 days 
and bone marrow was analyzed for GFP induction in different lineages. Overall GFP 
induction showed doxycycline dose-dependent induction in HSC, progenitors, B cell and 
myeloid cells, but very low induction in MEPs which can’t be enhanced by higher dose 
of doxycycline (Figure 4-7). No GFP was detected in WT bone marrow present or absent 
of doxycycline (Figure 4-7). 2mg/ml doxycycline reached the maximal induction which 
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Figure 4-4. GFP expression in peripheral blood of N1 progenies. 
(A). Different level of GFP% of peripheral blood of 9 founders’ N1 progenies 7 days post 
Doxycycline induction in drinking water. X-axis is founder ID and number of N1 of each 
founder tested. (B). Flow diagram of GFP expression in top 3 GFP induction N1s of each 
founder. Note GFP expression post doxycycline induction and diminished GFP 
expression once doxycycline was withdrew for 7 days. 
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Figure 4-5. Southern blot of TetO-sPrdm16 transgenic mice. 
(A). Southern blot on five transgenic founders showed 8005 carried more than one copy 
of transgene with multiple integrations. Rearrangement or deletion of transgene was also 
detected in 8005 genome. Other 4 transgenic founders demonstrated single copy of 
transgene with one integration. No rearrangement or deletion was found in those 
founders. (B). Southern blot on 8005 and its N1 progenies. Segregation of multiple 
integration occurred in N1 progenies. 8096 and 8100 carried the same integration pattern 
as founder 8005 while 8098 and 8219 carried only on copy of transgene with one 
integration. (C). Southern blot on 8005 N1 progeny (8098) and N2 progenies (8489, 8491 
and 8493). N2 progenies inherited transgene integration pattern from 8098. One copy of 
transgene with one integration was detected in N2 progenies, without rearrangement or 
deletion. 
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Figure 4-6. TetO-sPrdm16 transgene integration site by FISH and protein 
expression in transgenic bone marrow cells. 
(A). FISH conducted in transgenic mouse bone marrow cells showed transgene 
localization in mouse genome. Integration site of transgene in 8012 line was chromosome 
19B-C1 region, integration site in 8005S line was chromosome3C-D region and 
chromosome 2C-1 region in 8080 line. (B). sPRDM16 and GFP protein expression in 
transgenic bone marrow cells under the Doxycycline induction in vivo in all three 
founder lines. No sPRDMd16 and GFP protein expression was detected in wild type bone 
marrow cells and un-induced transgenic bone marrow cells. GAPDH was used as loading 
control for western blot. WT: wild type. Tg: Transgenics. Dox: Doxycycline. 
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Figure 4-7. GFP percentage in HSC, progenitor and mature lineages in transgenic 
bone marrow 39 days post doxycycline induction. 
(A). GFP percentage in singlets, B cells and Myeloid cells from transgenic bone marrow. 
(B). GFP percentage in HSC and progenitors from transgenic bone marro. 
(A) and (B) both demonstrated doxycycline dose-dependent GFP induction in mature, 
HSC and progenitor cells. Note low GFP induction in MEPs. 
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was not further increased by 5mg/ml (Figure 4-7). As a result 2mg/ml doxycycline will 
be used for the future experiment. TetOn-sPrdm16 transgenic mouse model is a useful 
tool to study role of sPrdm16 on HSC activity because of efficient induction of sPrdm16 
in HSCs. 
 
 
Overexpression of sPrdm16 abolishes HOXB4-mediated HSC expansion 
 
To evaluate sPrdm16’s effect on phonotypical HSC (CD150+CD48-Sca-1+c-
Kit
+
Lineage
-
) and MPP (Sca-1
+
c-Kit
-
Lineage
-
) frequency in HOXB4 expressing cells in 
vivo, bone marrow harvested from 18 weeks’ recipients were subjected to SLAM and 
MPP surface markers staining. mCherry and mCherry+sPrdm16 transplanted mice served 
as control. sPRDM16 alone didn’t alter MPP frequency compared with mCherry control 
transduced bone marrow cells. HOXB4 significant increased MPP frequency up to about 
5% of marking cells (Figure 4-8). Different from MPP, HSC frequency was doubled by 
sPRDM16 and further increased by HOXB4 (Figure4-8). However, sPRDM16 and 
HOXB4 double positive cells contained less HSCs, similar to control group (Figure 4-8). 
Results above suggest HOXB4 with or without sPRDM16 expression is able to increase 
MPP frequency. HOXB4, consistent with previous reports, increased the HSC frequency, 
which was diminished by sPRDM16 to control level. Lower HSC number but not MPP 
number implied that sustained expression of sPRDM16 is able to abolish HOXB4-
mediated HSC expansion but not MPP expansion. However, cell surface marker staining 
can be altered by certain transcription factor or microRNA expression
86
. The effect of 
HOXB4 and sPRDM16 on HSC frequency should be further confirmed by limiting 
dilution assay. 
 
Limiting dilution assay was carried out to assess sPRDM16’s effect on functional 
HSC frequency. Compared with mCherry only group, sPRDM16 didn’t significantly alter 
HSC frequency in recipient mice but HOXB4 recipients had about 10 time more HSCs 
compared with control (Table 4-1). When sPRDM16 was overexpressed in HOXB4 
expressing cells, HSC frequency was reduced about 25% relative to HOXB4 only group, 
indicating sustained expression of sPRDM16 in HOXB4 expressing cells indeed reduces 
HSC frequency and repression of Prdm16 by HOXB4 is necessary for HOXB4-mediated 
HSC expansion. 
 
 
Discussion 
 
PRDM16 is a hematopoietic stem cell regulator. It plays role in fetal liver HSC 
and neonatal HSC maintenance.
215,216
 It is preferentially expressed in quiescent LT-
HSCs,
215,216
 indicating its potential role in maintaining LT-HSC cell at quiescent status. 
Downregulation of Prdm16 was observed in HOXB4-expressing HSCs in vivo, raising 
the hypothesis that HOXB4 downregulates Prdm16 to drive HSCs to enter cell cycle to 
expand. To test the hypothesis we generated TetOn-sPrdm16 transgenic mice. Unlike 
constitutive overexpression vector, stable transgenic mouse model can avoid variation of 
gene expression and reduce the risk of vector rearrangement due to multiple 
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Figure 4-8. MPP and HSC frequency on marking cells. 
HOXB4 but not sPrdm16  increases MPP frequency. Sustained expression of sPRDM16 
in HOXB4 expressing cells maintain the same MPP frequency as HOXB4
+
 cells. 
sPRDM16 alone and HOXB4 alone both are able to increase HSC frequency about 2-2.5 
fold. Sustained expression of sPRDM16 in HOXB4 expressing cells decreased HSC 
frequency to control level. 
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Table 4-1. HSC frequency in HOXB4 and sPRDM16 transplanted mice. 
 
Group Dose Response Tested 
HSC 
frequency 
HSC low 
frequency 
HSC high 
frequency 
mCherry 2e5 3 7 
1 in 
462,515 
1 in 
1,416,998 
1 in 
150,967 
 4e4 0 6 
 8000 0 7 
 1600 0 6 
 320 0 7 
mCherry+sPRDM16 2e5 3 7 
1 in 
431,177 
1 in 
1,327,869 
1 in 
140,009 
 4e4 0 4 
 8000 0 6 
 1600 0 4 
 320 0 7 
HOXB4 2e5 7 7 
1 in 
43,606 
1 in 
92,131 
1 in 
20,639 
 4e4 5 7 
 8000 0 7 
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transductions. CMV promoter incorporated in TetOn construct allows moderate 
expression of sPRDM16 and may avoid cellular toxicity due to high level of PRDM16 
expression driven by MSCV promoter used in previous study. TetOn-sPrdm16 construct 
allows dose-dependent gene activation by adding different mount of doxycycline, which 
can prevent cellular toxicity. Expression of GFP was linearly correlated with sPRDM16 
expression level due to P2A element between sPrdm16 and GFP cDNA in the construct, 
which is usually not seen in IRES containing constructs. As a result, GFP intensity is a 
great indicator of sPRDM16 expression level. Since vector transduction resulted in 
limited number of Prdm16 transduced cells, transgenic mouse model is a great tool for in 
vivo study as it doesn’t require transductions and transgene can be activated in vivo 
directly.  
 
We generated three TetOn-sPrdm16 transgenic mouse lines. When induced, 
sPrdm16-GFP showed different induction efficiencies among 3 lines as well as different 
lineages within each transgenic line. The variation of sPrdm16 activation efficiency in 
each line may be due to the unique integration site of plasmid. We observed dose-
dependent GFP induction in mouse bone marrow as well as PB with best induction in 
SLAM population and worst in MEPs. Best GFP induction in SLAM cells, which are 
highly enriched HSCs, is consistent with highest endogenous Prdm16 expression 
compared with other lineages. However we noticed poor induction in MEPs though 
rtTA
M2
 was reported to have best induction efficiency in MEPs compared with other 
versions of rtTAs.
264
 Low induction efficiency of sPRDM16 on MEPs can be due to the 
sPRDM16 toxicity on MEPs which led to the elimination of MEPs from bone marrow. 
Although there was differential expression level of sPRDM16 cross the lineages, high 
induction efficiency of sPRDM16 on HSCs and progenitors except MEPs makes the 
TetOn-sPrdm16 transgenic mouse a great tool to study the role of sPRDM16 on HSC’s 
activity. 
 
To address why HOXB4 downregulates Prdm16 in transplanted mice, SLAM 
frequency and CRU were assessed in HOXB4 transplanted mice under the context of 
sustained expression of sPRDM16 through doxycycline induction. In HOXB4 only group 
SLAM frequency and CRU were increased compared to control group. There were 
reduced SLAM frequency and CRU in HOXB4 and sPRDM16 co-expressing group, 
indicating sustained expression of sPRDM16 can abolish HOXB4-mediated HSC 
expansion. Although changes in SLAM frequency and CRU in HOXB4 and sPRDM16 
coexpressing group were in the same trend, decrease in CRU was less significant than 
SLAM frequency. SLAM frequency was calculated on gated HOXB4 and sPRDM16 
double positive cells while CRU was assessed on the coexpressing group containing 
about 50% HOXB4 single positive
 
cells and only 10-30% HOXB4 and sPRDM16 double 
positive cells. With less double positive cells and more HOXB4 cells, effect of double 
positive cells on CRU could be compensated by HOXB4 single positive cells, which led 
to less significant changes in CRU than SLAM frequency. 
 
It is striking to detect less HSC when sPRDM16 was expressed in HOXB4 cells 
as PRDM16 was reported as a critical factor for HSC maintenance. We hypothesize that 
PRDM16 maintain HSC stemness by maintaining HSC quiescence. HOXB4 represses 
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Prdm16 to release HSC to cell cycle, thus expands HSC in vivo. To test this hypothesis 
cell cycle status can be evaluated in HOXB4 and sPRDM16 expressing cells from 
transplanted mice and we expect cell cycle arrest of double positive cells. At meanwhile 
enhanced apoptosis or downstream differentiation of HSCs also can be the alternative 
explanation of reduced HSCs by sustained sPRDM16 expression on HOXB4 cells.  
 
In this chapter we generated TetOn-sPrdm16 inducible transgenic mouse model 
which demonstrated doxycycline dose-dependent sPRDM16/GFP expression in 
hematopoietic lineages except MEPs. Using this mouse model we showed that sustained 
expression of sPRDM16 on HOXB4 expressing cells can abolish HOXB4-mediated HSC 
expansion in transplanted mice. Mechanism how sPRDM16 decreases HSC frequency 
under the context of HOXB4 overexpression is not included in this chapter but can be 
explored in the future studies. 
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CHAPTER 5.    DISCUSSION 
 
 
Significance 
 
The object of this study is to understand molecular mechanism of HOXB4-
mediated HSC benign expansion in vivo. It started with gene expression array of HOXB4 
expressing LSK cells from transplanted mice and then we focused on Prdm16, one of the 
most significant downregulated genes, to study its role on HOXB4-HSC benign 
expansion. Results of this study revealed some interesting aspects of HOXB4-mediated 
HSC expansion. 
 
 
HOXB4 is a global regulator of HSC self-renewal  
 
In this study gene expression prolife of HOXB4 expressing LSKs cells from 
transplanted mice revealed a dynamic transcriptional network of HOXB4 during the 
reconstitution. In order to expand HSCs, HOXB4 activated hematopoietic stem cell 
pathway and hematopoietic stem cell long term pathway. Expression of genes regulating 
HSC function were altered by HOXB4, such as Hemgn, Gata2, N-myc, Pten, Bcl-3, 
Prdm16, Jun, HOXA9 and many others, which led to balanced HSC expansion. Besides 
HSC expansion, HOXB4 also facilitate B cell lineage and myeloid lineage priming at 
LSK cell level. As a result of differentiation permission, HOXB4 is able to control the 
HSC pool size and prevent the leukemia, a great feature of HOXB4 but not seen in any 
other oncogenic HOX factors such as HOXA9 and HOXA10. In summary HOXB4 is a 
global regulator of HSC self-renewal. HOXB4-mediated benign HSC expansion is not 
achieved by a single downstream target or pathway. It is an outcome of highly complex 
regulation of genes and pathways playing roles in HSC proliferation, differentiation and 
apoptosis, which leads to balanced HSC expansion. Besides the knowledge we gained in 
this study, role of HOXB4 in HSC expansion in vivo is a very interesting topic in the 
hematology field and worthwhile for further exploration. 
 
 
Differential regulation of Prdm16 transcript by HOXB4 and HOXA9/A10 
 
Our study revealed that downregulation of Prdm16 is unique for HOXB4 but not 
for HOXA9 and HOXA10 in HSCs. HOXB4, HOXA9 and HOXA10 belong to HOX 
family. HOX genes all bind to a similar set of ‘AT’-rich DNA binding site through their 
homeodomain and the non-homeodomain adjacent to the homeodomain offer additional 
HOX-DNA-binding specificity. A bacterial one-hybrid approach (B1H) and in vivo 
protein-binding microarrays (PBMs) showed that the ‘AT’-rich DNA consensus 
sequences HOXB4 and HOXA9/A10 recognize and bind to are different (Figure 5-1), 
suggesting HOXB4 and HOXA9/A10 may bind to different region of Prdm16 promoter 
or enhancer. This can be one of the mechanisms of differential transcription regulation of 
Prdm16 by HOXB4 and HOXA9/A10. There is a study suggesting that HOX gene can  
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Figure 5-1. Comparison of in vitro and in vivo Hox-binding site preferences.  
Shown are LOGO diagrams summarizing Hox-binding site preferences for Hox4 and 
Hox9-13 groups. The column on the left lists the LOGOs generated using the binding 
sites identified by the B1H method. The column on the right lists the LOGOs generated 
using the protein-binding microarrays. Y-axis is nucleotide frequency. 
 
Modified with permission. Mann RS, Lelli KM, Joshi R. Hox specificity unique roles for 
cofactors and collaborators. Curr Top Dev Biol. 2009;88:63-101. 
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use transcription repressors as HOX cofactors in gene repression. Selectively using 
repressor by HOXB4 but not HOXA9 and HOXA10 can be the explanation of HOXB4-
mediated Prdm16 repression. HOX collaborators are another group of proteins which 
binds to HOX factors or HOX-targeted elements to determine target genes are activated 
or repressed. Protein-protein interaction between HOX factors and collaborators may 
form enhanceosome-like structure on HOX-targeted region to activate target genes 
expression. HOXB4 and HOXA9/A10 may form transcription complex with different 
collaborators and determine whether to active or repress Prdm16 transcription.
114
 
 
 
HOXB4 doesn’t cause leukemia unless pro-oncogenes are activated 
 
HOXB4 is always considered as a safe factor to expand HSCs, because 
overexpression of HOXB4 doesn’t lead to hematopoietic malignancies. Safety issue was 
brought back to discussion when the two myeloid leukemia cases from a dog and a 
macque who received HOXB4 transduced CD34
+
 cells
187
 were reported. In our 
independent screening we also detected two myeloid leukemias derived from HOXB4 
expressing cells in transplanted mice. Both studies revealed additional genetic lesions in 
leukemic cells due to vector integration and activation of sPrdm16 was common in both 
studies, indicating HOXB4 is doesn’t transform hematopoietic cells unless additional 
oncogenes are activated and activation of sPRDM16 is one of the factors contributing to 
the leukemogenesis. Leukemic cells line generated from the leukemic dog demonstrated 
sPRDM16-dependent growth in vitro. However, it is possible the leukemias with 
sPrdm16 activation may be purely due to sPrdm16 expression and HOXB4 was not at all 
involved. In our study we didn’t detect any hematopoietic malignancies when sPrdm16 
was overexpressed alone. Shing D.C et al also claimed that sPrdm16 was not oncogenic 
in WT mice but in p53 null mice.
248
 Both studies suggest sPrdm16 alone is not sufficient 
to cause leukemia. So our screening together with previous literature reports support the 
synergistic role of HOXB4 and sPRDM16 in leukemogenesis.  
 
 
Oncogenic potential of sPRDM16 
 
sPRDM16 is the short form of PRDM16 with partial deletion of N-terminal PR 
domain. sPRDM16 but not PRDM16 is considered as a proto-oncogene
189
 and is 
associated human hematopoietic malignancies. Absence of the PR domain may count for 
the oncogenic potential of sPRDM16. PR domain is 20-30% identical to SET domain, 
indicating the potential role of PRDM16 as a methyltransferase. sPRDM16 is highly 
homologous to EVI1, zinc finger part of MDS1/EVI1 (PRDM3) protein. EVI1 is 
oncogenic and aberrant expression of EVI1 is detected in about 10% of AML cases
265
 
and is able to induce MDS in mice.
266
 Similar to Prdm16, EVI1 gene expression is 
upregulated in NUP98-HOXA9-expressing leukemia cells.
267
 Several mechanisms have 
been identified to contribute to the leukemogenic activity of EVI1 which can be shared 
by sPRDM16. EVI1 exerts negative regulation on TGF-β signaling pathway through the 
repression of Smad3 function, which promotes cellular proliferation and affects cellular 
differentiation. EVI1 also suppresses the JNK-1-mediated phosphorylation of c-JUN or 
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inhibits interferon-α signaling to exert anti-apoptotic effects.268,269 Recent studies showed 
that EVI recruits and forms protein complex with several Polycomb proteins to PTEN 
locus and switch PTEN promoter from H3K27Ac status to H3K27m3 status to repress 
Pten expression, which activates PI3K/ARK/Mtorc1 signaling in leukemia cells.
270,271
 
Mechanisms of leukemogenic potential of EVI1 mentioned above suggest that EVI1 
unique regulation of certain pathways and recruitment of epigenetic modifiers confer 
EVI1’s oncogenic activity and lack of HMT activity from PR domain is not the reason. 
sPRDM16 can induce leukemia in the similar manner as EVI1 due to the structural and 
biology similarities between them. 
 
 
MDS/AML genetic lesion is missing from HOXB4/sPrdm16 preleukemia model 
 
When sPrdm16 and HOXB4 were co-overexpressed, only 2 out of 12 recipients 
developed preluekmias at 28 or 32 weeks post transplantation. Two preleukemic cases 
represent MDS/AML phenotype with normal karyotype. Low incidence may be due to 
low cotransduction efficiency. However, the long latency for leukemogenesis indicates 
activation sPrdm16 and HOXB4 are not sufficient to cause leukemic transformation. 
MDS/AML is a heterogeneous group of hematopoietic stem cell disorders and acquired 
mutations such as NPM1
272
, TET2
273
 and FLT3
274
 were well characterized in sporadic 
cases of AML. Submicroscopic deletion of 5q was recently identified in a patient with 
MDS presenting with normal karyotype resulting in loss of tumor suppressor CTNNA1 
and HSPA9.
275
 ASXL1frameshift/stop mutation (591*), EZH2 point mutation (R690H), 
RUNX1 frameshift/ stop mutations (c.474dupT and c424_425ins11bp) and TET2 
frameshift/stop mutations (c.1510_1513delAAAA and R1465*) were also detected as 
MDS-associated mutations.
275,276
 RUNX1 mutations are frequently detected in de novo 
AML with noncomplex karyotype and were proposed as clinical biomarkers for disease 
progression of MDS to AML.
277
 Harriet Holme et al
278
 reported genetic categorization of 
27 families with familial MDS/AML, revealing heterozygous mutations in the GATA2 
gene (c.121C>G p.Pro41Ala; c1187G>A p. Arg396Gln and c1061C>T, p.Thr354Met), 
TERT mutations, TERC mutations and RUNX1 mutation. There are also MDS/AML 
cases with unidentified mutations. One or many of the mutations mentioned above may 
be required for the complete MDS/AML transformation in our HOXB4 and sPrdm16 
transplanted animals, missing which led to delayed onset of the leukemias.  
 
 
Repression of Prdm16 may promote cell enter cell cycle and facilitate HOXB4-
mediated HSC expansion 
 
Expansion of HSCs requires HSCs to enter cell cycle. PRDM16 shared high 
similarity of MDS1/EVI1protein, suggesting the PRDM16 may share similar mechanism 
how MDS1/EVI1 regulate HSC self-renewal can. MDS1/EVI1 was shown to be negative 
cell cycle regulator, loss of which led to increased proportion of active dividing HSCs 
and HSC exhaustion.
218
 Endogenous Prdm16 is highly expressed in quiescent LT-HSCs 
and loss of Prdm16 increased the proportion of HSCs undergoing active cell 
division.
215,216
  We detected marked repression of Prdm16 in HOXB4-HSCs. It is 
 91 
possible that HOXB4 represses Prdm16 to release HSCs from cell cycle arrest state. 
When sPrdm16 expression is sustained in HOXB4 expressing cells, HSC proliferation 
can be suppressed, which results in reduced phonotypical and functional HSCs number 
observed in this study, supporting the hypothesis that repressing Prdm16 in HOXB4 
expressing cells is required for HOXB4-mediated HSC expansion. Loss of Prdm16 also 
induces apoptosis/cell death in HSCs.
215,216
 Repression of Prdm16 by HOXB4 can be a 
mechanism to induced apoptosis in unwanted proliferating HSCs, which is contradict to 
our previous finding that HOXB4 indeed protects hematopoietic progenitors from 
apoptosis. Although how HOXB4 downregulates Prdm16 in transplanted mice is 
unknown, but it is clear sustained expression of sPrdm16 decreased HSC frequency in 
HOXB4 transplanted mice. In conclusion, repression of Prdm16 is required for HOXB4-
mediated HSC expansion in vivo. 
 
 
Future Directions 
 
HOXB4-mediated HSC expansion is an interesting topic. Findings of our study 
revealed the unique regulation of Prdm16 by HOXB4 during HSC expansion in vivo. 
Considering the limitations discussed above, several experiments can be carried out to 
improve this study. 
 
Our study showed significant downregulation of Prdm16 by HOXB4 in 
transplanted mice. To address the question how HOXB4 downregulates Prdm16, ChIP 
assay can be performed. We have generated HOXB4-dependent myeloid cell line. This 
cell line contains Gr1
-
Mac1
-
FcɛR- primitive population which demonstrated HOXB4-
dependent proliferation and myeloid progenitor self-renewal capacity. We have 
conducted ChIP assay using I12 HOXB4 monoclonal antibody and HOXB4 protein 
enrichment was nicely achieved. However, ChIP-seq data showed low signal-to-noise 
ratio which makes peak calling impossible. High noise can be due to low specificity of 
the HOXB4 antibody or non-stringent washing condition, both can be improve by 
changing to a ChIP-grade antibody and more stringent washing solution. But non-specific 
binding of HOXB4 to mouse genome due to high expression level of HOXB4 by 
overexpression vector can also contribute to the high noise. Lower the protein expression 
by switching to weak promoter probably can decrease the noise. 
 
As mentioned above another question is not answered by our study is how 
downregulation of Prdm16 contributes to the HSC expansion in HOXB4 transplanted 
mice. Given the fact that loss of Prdm16 release HSC into cell cycle,
215,216
 repression of 
Prdm16 can set HSC at active proliferation state, thus allowing HSC expansion. To test 
the hypothesis, cell cycle analysis can be done on HSC compartment of HOXB4 and 
sPRDM16 co-expressing cells and we predict higher proportion of G0 cells in HOXB4 
and sPRDM16 double positive HSCs than HOXB4 single positive HSCs. 
 
Prdm16 was claimed as a hematopoietic stem cell regulator.
216
 Mechanistic 
studies regarding its role in hematopoietic specification and HSC maintenance are 
lacking. Numerous studies have identified molecular mechanism of Prdm16-mediated 
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brown fat maturation, including complex elements, upstream regulators and downstream 
pathways. Prdm16 was also reported to maintain heterochromatin integrity through its 
H3K9me1 methyltransferase activity. As one of the long-term directions, molecular 
interaction of Prdm16 with other factors and involvement of Prdm16 in epigenetic 
modification during embryonic and adult hematopoiesis can be explored, findings of 
which will provide great insight of HSC biology. 
 
Our study showed that oncogenic HOXA9 and HOXA10 upregulated Prdm16 up 
to about 50 fold compared with HOXB4 in HSC compartment, suggesting aberrant 
expression of Prdm16 could be a major player in HOXA9 or HOXA10-associated 
leukemia initiation or maintenance. If so, overexpression of HOXA9/10 in Prdm16 null 
HSCs but not WT HSCs will not lead to leukemia. It will be exciting to confirm the role 
of Prdm16 and identify Prdm16 pathway in HOXA9/10-asscoiated leukemia. Drug 
screening can be conducted to identify promising compounds targeting Prdm16 pathway 
associated with HOXA9/10 leukemia. 
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